FYI-1193-0904

FYI Initial

**American Petroleum Institute**
1220 L Street, Northwest
Washington, D.C. 20005

**Contains No CBI**

**Robert T. Drew, Ph.D.**
Director, Health and
Environmental Sciences
(202) 682-8308
(202) 682-8270 (FAX)

FYI-93-000904
INIT 11/15/93

84940000005

OFFICE OF POLLUTION PREVENTION AND TOXICS
93 NOV 15 PM 12:23 REC'D

FYI Coordinator
OTS Document Processing Center (TS-790)
U.S. EPA, Room 421-B East Tower
401 M St. SW
Washington DC 20460

November 10, 1993

Dear FYI Coordinator:

In accordance with API's policy of providing the federal government with copies of research designed to determine whether any chemical substance or mixture manufactured, processed or distributed by API member companies may cause a risk of injury to health or the environment, we are enclosing a copy of the following draft final report:

**(Identification no: FYI not assigned) Effects of Dermal Exposure to Petroleum Middle Distillates on Irritation and Epidermal Hyperplasia in Mouse Skin. Draft Final. API 6037-001.**

NOV 17 REC'D

Please note that this information is provided in accordance with the full disclosure policy of API and does not constitute a formal submission as required by a test rule.

This document does not contain confidential information. If you have any questions, please communicate with me.

Sincerely,

Robert T. Drew, Ph.D.

21 JULY 1993

Contains No CBI

# EFFECTS OF DERMAL EXPOSURE TO PETROLEUM MIDDLE DISTILLATES ON IRRITATION AND EPIDERMAL HYPERPLASIA IN MOUSE SKIN

**Subprotocol 3**
**Draft Final**

JUL 26 1993

**Project Number: API 6037-001**

RECD
OFFICE OF POLLUTION
PREVENTION AND TOXICS
93 NOV 15 PM 12: 23

*Submitted to*

Dermigen, Inc.
908 North East Third Street, Loop 230
Smithville, TX 78957

**ManTech Environmental Technology, Inc.**
*A ManTech International Company*

# EFFECTS OF DERMAL EXPOSURE TO PETROLEUM MIDDLE DISTILLATES ON IRRITATION AND EPIDERMAL HYPERPLASIA IN MOUSE SKIN

**Project No.:** API 6037-001

**Test Material:** Petroleum Middle Distillates

**Contractor:** ManTech Environmental Technology, Inc.
Five Triangle Drive
Research Triangle Park, North Carolina 27709

**Sponsor:** Dermigen, Inc.
908 North East Third Street
Loop 230
Smithville, Texas 78957

| | |
|---|---|
| Study Initiation: | April 5, 1993 |
| Initiation of Dosing: | April 29, 1993 |
| Completion of In-Life Phase: | May 14, 1993 |

## SUMMARY

Twenty-seven groups of 16 female CD-1 mice each were dosed according to the Table in II.I. An approximate area of 2.5 X 4 cm of the dorsoscapular area was shaved two days prior to the first dose. Each mouse was dosed with 200 µl (100 µL if test agent was undiluted) on April 29, 1993 (Thursday), May 3, 1993 (Monday), May 6, 1993 (Thursday) and May 10, 1993 (Monday). All animals were observed for dermal irritancy 24 h after each dose and remaining animals 72 h after the last dose. Signs of gross dermal irritation were observed in eight of the animals from the toluene dose; fourteen from the mineral seal oil (MSO):toluene dose; two from the 23.5 µL odorless light petroleum hydrocarbon (OLPH) dose; one from the 50 µL OLPH dose; eleven from the 100 µL OLPH dose; four from the 11.8 µL MSO dose; six from the 23.5 µL MSO dose; eight from the 50 µL MSO dose; twelve from the 100 µL MSO dose; three from the 11.8 µL Light Vacuum Distillate (LVD) dose; three from the 23.5 µL LVD dose; five from the 33.3 µL LVD dose; nine from the 100 µL LVD dose; three from the 0.2125 nmol TPA dose; five from the 0.85 nmol TPA dose; seven from the 3.4 nmol TPA dose; thirteen from the 13.6 nmol TPA dose; two from the 10 mg n-dodecane dose; four from the 25 mg n-dodecane dose; four from the 50 mg n-dodecane dose; five from the 100 mg n-dodecane dose; one from the 1 mg benzoyl peroxide dose; five from the 5 mg benzoyl peroxide dose; three from the 10 mg benzoyl peroxide dose; and two from the 20 mg benzoyl peroxide dose. Minimal [defined as dried skin] to marked desquamation was observed in approximately 99% of all the mice exhibiting signs of dermal irritancy. Minimal to marked erythema was exhibited in thirty-two mice, minimal to marked eschar in six mice, and minimal to moderate fissuring in two mice. There were no significant body weight gain differences in any of the groups when compared to the negative control (acetone) group (Table 2; Figure 2). Four mice from each group were sacrificed 6, 24, 48 and 96-h after receiving the last dose. Thirty minutes prior to scheduled necropsy at 24, 48 and 96-h after the last dose, each animal received bromodeoxyuridine (BrdUrd) intraperitoneally at a concentration of 100 µg/gm of body weight. Mice scheduled for necropsy were killed by cervical dislocation. Skin from the treated area was collected for ornithine decarboxylase (ODC) activity and cryopreservation at 6 and 24-h necropsies while skin, pancreas and duodenum were collected for histopathological evaluation and cryopresevation at the 6, 24, 48 and 72-h necropsies. The histopathological evaluation was performed under a separate contract and not part of this report. The skin samples for ODC were collected, scraped, homogenized, and frozen at -70°C. The homogenates were shipped on dry ice to Dermigen May 24, 1993.

## PERSONNEL

| | |
|---|---|
| Study Director: | Dr. Sheela Sharma |
| Study Supervisor: | Mr. Allen Ledbetter |
| Dosing: | Ms. Gail Wyatt |
| Weighing and Dermal Irritancy Scoring: | Ms. Gail Wyatt<br>Ms. Billie Sumrell<br>Ms. Merrie Burnett |
| Sacrifice Mice: | Mr. Allen Ledbetter |
| Prosectors: | Ms. Elisabeth Korytynski<br>Ms. Bonnie Hamby<br>Ms. Debbie Mitchell |
| Collection of Epidermis: | Ms. Merrie<br>Mr. Kyle Garris |
| Cryopreservation: | Ms. Betty Wilkinson |

This report was prepared by Ms. Gail Wyatt, Mr. Allen Ledbetter and Dr. Sheela Sharma

Submitted by: _____ Date: _____
Dr. Sheela Sharma

Approved by: _____ Date: _____
Dr. Earl Walborg

# TABLE OF CONTENTS

I. Introduction ..... 5
II. Materials and Methods ..... 5
A. Test Articles ..... 5
B. Animals ..... 5
C. Animal Maintenance ..... 5
D. Animal Water ..... 6
E. Animal Feed ..... 6
F. Animal Room Environment ..... 6
G. Assignment to Groups ..... 6
H. Test Article Dosage Preparation ..... 6
I. Design of the Study ..... 8
J. Dosing Schedule ..... 9
K. Body Weights ..... 9
L. Clinical Observations ..... 9
M. Assessment of Gross Dermal Irritancy ..... 9
N. Sacrifice Schedule ..... 9
O. Sacrifice and Skin Preparation ..... 11
P. Necropsy ..... 11
Q. Epidermal Homogenization ..... 12
R. Statistical Methods ..... 12
Figure 1 - Skin Specimen Diagram ..... 11

III. Results ..... 12
A. Animal Survival ..... 12
B. Body Weights ..... 12
C. Clinical Observations ..... 14
D. Dermal Irritancy ..... 14
E. Necropsy ..... 14
F. Protocol Deviations ..... 14
Figure 2-Body Weight Gains ..... 13

IV. Tables ..... 15
Table 1-Individual Body Weights and Body Weight Gains ..... 16
Table 2-Mean Body Weights and Body Weight Gains ..... 23
Table 3-Individual Dermal Irritancy Scores ..... 24
Table 4-Total Dermal Irritancy Scores ..... 51
Table 5-Gross Necropsy Observations ..... 60

V. Appendices ..... 61
Appendix 1-Animal Health Report ..... 62
Appendix 2-Feed Analysis ..... 63

## I. Introduction

The purpose of this study is to establish a data base for designing and implementing a comparative study to measure the effects of petroleum middle distillates on dermal irritancy and markers of tumor promotion in mouse skin to the human situation. These data will be used to design subsequent studies on sequential skin biopsies, and human skin xenografts in nude mice.

Sub-protocol 3 was expanded to compare the effects of three petroleum middle distillates to the efficacy of two structurally different skin tumor promoters, TPA and benzoyl peroxide by assessing dermal irritation and two markers of tumor promotion (i.e. sustained epidermal hyperplasia and ornithine decarboxylase (ODC) activity). We previously found that n-dodecane produced dose-dependent induction of ODC. Using identical samples, Science Park Institute comfirmed its positive tumor-promoting ability and therefore n-dodecane was included in subprotocol 3 as a positive control. This report summarizes the in-life portion of the study and the homogenization of skin samples for ODC evaluation.

## II. Materials and Methods

A. Test Articles: The test article, 12-O-tetradecanoylphorbol-13-acetate (TPA), CAS # 57716-89-9, Lot # F131, 99+% purity was received on April 13, 1993 from LC Services, Inc., Woburn, MA. TPA was stored in its original container (glass ampule) and kept frozen (-20°C) until just prior to dosing. Acetone, Lot No. 2435 KAVY (99.6% purity) was received from Mallinckrodt Chemicals Co., stored in a glass amber bottle at room temperature. Toluene, Lot No. 04444CZ (> 99% purity) was received from Aldrich Chemical Co., and stored in a glass amber bottle at room temperature. Three middle distillates, an odorless light hydrocarbon (OLPH), a mineral seal oil (MSO), and a light vacuum distillate (LVD) were received August 4, 1992 and stored at room temperature. n-Dodecane was received on February 10, 1992, lot # PY-03547KY, and stored at 0°C under nitrogen. Benzoyl Peroxide, lot# MZ 06613KY, 97% purity, was received April 13, 1993 and stored at 4°C with dessicant present. Five grams of BrdUrd, lot #32H0779, was received from Sigma July 31, 1992 and stored below 0°C with dessicate.

B. Animals: Specific pathogen-free, female CD-1 mice (40-47 days old at the time of receipt) were received in autoclaved, filtered cartons on April 5, 1993 from Charles River Laboratories, Inc., Quebec, Canada. Health records (Appendix 1) of the supplier's breeding colony did not show any health related conditions that could affect the results of this study.

C. Animal Maintenance: The mice were quarantined for three weeks in MTC room # 137. During this time they were observed daily for disease or any condition which would render them unsuitable for inclusion in the study. After two weeks of quarantine, the

mice were single housed in stainless-steel cages (Allentown Caging Equipment Co., Allentown, NJ). Near the end of quarantine, the mice were randomized into dosing groups (See Table Section II.1), ear tagged, and placed consecutively in the cage units according to the dosing schedule. The cage unit and cage dimensions comply with current ILAR/AAALAC caging requirements.

D. Animal Water: City of Durham water (filtered and deionized by ManTech Environmental) was provided *ad libitum* to each cage via automatic watering.

E. Animal Feed: Animals were provided Purina 5002 Certified Rodent Chow (pellets) in stainless steel feeders *ad libitum* during the study. All feed used in this study was stored at ~5°C. See Appendix 2 for feed analysis.

F. Animal Room Environment: The animal room was environmentally controlled to maintain temperature in a range of 69 to 74°F and a relative humidity of 55 to 57%. Temperature and humidity were recorded twice daily, once daily on weekends. Fluorescent lighting was provided automatically on a 12 h light, 12 h dark cycle (lights on from 0600-1800). In the room where the dosing or bromodeoxyuridine (BrdUrd) injections were done, yellow light was used to make sure there was no degradation of the light sensitive chemicals. A back-up electrical generator was on-line to ensure animal room environments were maintained in case of power failure.

G. Assignment to Groups: At the end of the quarantine period, on April 27, 1993 (Study Day -2), the dorsoscapular region (2.5 x 4 cm) of the back was shaved using an Oster® electric shaver with a No. 40 clipper blade. Shaving was performed in a manner that minimized abrasions, and shaving heads were frequently changed to avoid heating the skin. Multiple shavers were used, and the blades were cleaned with a brush and ethanol. The mice were then weighed and given physical examinations to ensure their suitability as test subjects (mice that were abraised during shaving were eliminated from the study). The mice were assigned to their respective groups by a stratified random method using a computer program. The randomized body weights for the animals ranged from 23.5 to 31.4 g.

H. Test Article Dosage Preparation: A stock solution of TPA in acetone was prepared on April 29, 1993 and stored at -20°C. TPA and the remaining test agent dilutions were prepared fresh each day just prior to dosing.

TPA

Stock Solution: 1 mg TPA + 1.193 mL Acetone = 838 μg/mL

a. 13.6 nmol = 0.3 mL (Stock Solution) + 5.7 mL Acetone

b. 3.4 nmol = 1.5 mL (a) + 4.5 mL Acetone

c. 0.85 nmol = 1.5 mL (b) + 4.5 mL Acetone

d. 0.2125 nmol = 1.5 mL (c) + 4.5 mL Acetone

**OLPH and MSO**

a. 100 µL = Neat

b. 50 µL = 1.5 mL (a) + 4.5 mL Acetone

c. 23.5 µL = 1 mL (a) + 7.5 mL Acetone

d. 11.8 µL = 2.5 mL (c) + 2.5 mL Acetone

**LVD**

a. 100 µL = Neat

b. 33.3 µL = 1 mL (a) + 5 mL Acetone

c. 23.5 µL = 1 mL (a) + 7.5 mL Acetone

d. 11.8 µL = 2.5 mL (c) + 2.5 mL Acetone

**n-Dodecane**

a. 100 mg = 5.33 mL (Neat) + 2.67 mL Acetone

b. 50 mg = 3.5 mL (a) + 3.5 mL Acetone

c. 25 mg = 2.5 mL (b) + 2.5 mL Acetone

d. 10 mg = 0.5 mL (a) + 4.5 mL Acetone

**Benzoyl Peroxide**

a. 20 mg = 1 gram (Neat) + 10 mL Acetone

b. 10 mg = 4 mL (a) + 4 mL Acetone

c. 5 mg = 3 mL (b) + 3 mL Acetone

d. 1 mg = 1 mL (c) + 4 mL Acetone

**Mineral Seal Oil:Toluene (1:1)**

2.5 mL MSO (Neat) + 2.5 mL Toluene (Neat)

I. Design of the Study: Groups of 16 female mice were administered the test agents dermally to the shaven backs (dorsoscapular area) at doses according to the following schedule. All doses were administered dermally at a constant volume of 200 µL per animal (100 µL when the test agent was applied neat) using a pipette (Oxford Labware, St. Louis, MO). The treatment groups were as follows:

| Group | Test Agent | Animal # | Dose |
|---|---|---|---|
| 1 | Toluene | 1-16 | 0 |
| 2 | Acetone | 17-32 | 200 µL |
| 3 | MSO:Toluene | 3-48 | 200 µL |
| 4 | OLPH | 49-64 | 11.8 µL |
| 5 | OLPH | 65-80 | 23.5 µL |
| 6 | OLPH | 81-96 | 50 µL |
| 7 | OLPH | 97-112 | 100 µL |
| 8 | MSO | 113-128 | 11.8 µL |
| 9 | MSO | 129-144 | 23.5 µL |
| 10 | MSO | 145-160 | 50 µL |
| 11 | MSO | 161-176 | 100 µL |
| 12 | LVD | 177-192 | 10 mg |
| 13 | LVD | 193-208 | 25 mg |
| 14 | LVD | 209-224 | 50 mg |
| 15 | LVD | 225-240 | 100 mg |
| 16 | TPA | 241-256 | 1.7 nmol |
| 17 | TPA | 257-272 | 3.4 nmol |
| 18 | TPA | 273-288 | 6.8 nmol |
| 19 | TPA | 289-304 | 13.6 nmol |
| 20 | n-Dodecane | 305-320 | 10 mg |
| 21 | n-Dodecane | 321-336 | 25 mg |
| 22 | n-Dodecane | 337-352 | 50 mg |
| 23 | n-Dodecane | 353-368 | 100 mg |
| 24 | Benzoyl Peroxide | 369-384 | 1 mg |
| 25 | Benzoyl Peroxide | 385-400 | 5 mg |
| 26 | Benzoyl Peroxide | 401-416 | 10 mg |
| 27 | Benzoyl Peroxide | 417-432 | 20 mg |

Not correct

Each of these treatment groups received volume of 200 µL except groups 7, 11, and 15. The amount of test agent remains as is.

J. Dosing Schedule: The first day of dosing was April 29, 1993. Subsequent doses were administered on May 3 and May 6, 1993, and the final dose administered on May 10, 1993. All of the dosings were administered between 0800 and 1200. On the last dose day, four animals/group scheduled for sacrifice were necropsied 6 h post-dose. The remaining animals (four per group) were sacrificed at 24, 48 and 96 h post-dose.




a=necropsy performed, b=tissues taken for histology, c=ODC analysis, d=BrdUrd injection

K. Body Weights: All animals were weighed two days prior (Study Day -2) to the initiation of dosing and again on the final dose day (Study Day 12).

L. Clinical Observations: Each animal was observed for signs of morbidity or mortality twice daily on weekdays (am and pm) and once daily on weekends throughout the study.

M. Assessment of Gross Dermal Irritancy: All animals were observed for gross signs of dermal irritancy approximately 24 h after the dermal dosing and 72 h following the last dose. The following parameters were assessed: erythema, desquamation, eschar, alopecia, discoloration, fissuring, and ulceration.

N. Sacrifice Schedule: Four animals/group were sacrificed at 6, 24, 48 and 96 h following the last dose. Thirty minutes prior to scheduled necropsy at 24, 48 and 96 h after the last dose, each animal received BrdUrd intraperitoneally at a concentration of 100 $\mu$g/gm of body weight. BrdUrd was dissolved in sterile phosphate-buffered saline approximately one hour before dosing and administered such that the volume for injection ranged from 0.1-0.2 ml. Refer to the Sacrifice Schedule on the following page for animal numbers and the order in which they were sacrificed.

## SACRIFICE SCHEDULE

| Group | Chemical | Animal Number 6-h | Animal Number 24-h | Animal Number 48-h | Animal Number 96-h |
|---|---|---|---|---|---|
| 1 | Toluene | 1-4 | 5-8 | 9-12 | 13-16 |
| 2 | Acetone | 17-20 | 21-24 | 25-28 | 29-32 |
| 3 | MSO:Toluene | 33-36 | 37-40 | 41-44 | 45-48 |
| | OLPH | | | | |
| 4 | 11.8 µl | 49-52 | 53-56 | 57-60 | 61-64 |
| 5 | 23.5 µl | 65-68 | 69-72 | 73-76 | 77-80 |
| 6 | 50 µl | 81-84 | 85-88 | 89-92 | 93-96 |
| 7 | 100 µl | 97-100 | 101-104 | 105-108 | 109-112 |
| | MSO | | | | |
| 8 | 11.8 µl | 113-116 | 117-120 | 121-124 | 125-128 |
| 9 | 23.5 µl | 129-132 | 133-136 | 137-140 | 141-144 |
| 10 | 50 µl | 145-148 | 149-152 | 153-156 | 157-160 |
| 11 | 100 µl | 161-164 | 165-168 | 169-172 | 173-176 |
| | LVD | | | | |
| 12 | 11.8 µl | 177-180 | 181-184 | 185-188 | 189-192 |
| 13 | 23.5 µl | 193-196 | 197-200 | 201-204 | 205-208 |
| 14 | 33.3 µl | 209-212 | 213-216 | 217-220 | 221-224 |
| 15 | 100 µl | 225-228 | 229-232 | 233-236 | 237-240 |
| | TPA | | | | |
| 16 | 0.2125 nmol | 241-244 | 245-248 | 249-252 | 253-256 |
| 17 | 0.85 nmol | 257-260 | 261-264 | 265-268 | 269-272 |
| 18 | 3.4 nmol | 273-276 | 277-280 | 281-284 | 285-288 |
| 19 | 13.6 nmol | 289-292 | 293-296 | 297-300 | 301-304 |
| | Dodecane | | | | |
| 20 | 10 mg/mL | 305-308 | 309-312 | 313-316 | 317-320 |
| 21 | 25 mg/mL | 321-324 | 325-328 | 329-332 | 333-336 |
| 22 | 50 mg/mL | 337-340 | 341-344 | 345-348 | 349-352 |
| 23 | 100 mg/mL | 353-356 | 357-360 | 361-364 | 365-368 |
| | BPX | | | | |
| 24 | 1 mg/mL | 369-372 | 373-376 | 377-380 | 381-384 |
| 25 | 5 mg/mL | 385-388 | 389-392 | 393-396 | 397-400 |
| 26 | 10 mg/mL | 401-404 | 405-408 | 409-412 | 413-416 |
| 27 | 20 mg/mL | 417-420 | 421-424 | 425-428 | 429-432 |

O. Sacrifice and Skin Preparation: Single groups of four mice each were killed by cervical dislocation. Each animals cage card was removed and placed with the body to avoid mixup of animals. The dead mice were then shaved (when required), and a depilatory (Nair™) was applied to the back. The depilatory was removed after five minutes by gentle scrubbing, with a gloved finger, under cold running tap water. The group of four mice was then placed in a pan of ice (dorsal side down), with extra ice covering the ventral side, until necropsy.

P. Necropsy: The prosector team was given only one group of four mice at a time to avoid mixing up tissues. Each prosector received two tissue cassettes with a matching number of the mouse they were necropsying. An approximate area of 2.5 X 4 cm of the dorsoscapular area was removed, spread out on a cutting board, and a template was used to guide the exact size measurement. Using a razor to cut downward, the skin was divided according to the following diagram:




1 Specimen (1 x 1 cm) for ODC assay

2 Specimens (0.5 x 2 cm each) for histopathology, morphometric assay of epidermal hyperplasia, and determination of labeling and proliferation indices. Specimen 2b will be evaluated. Specimen 2a will serve as a reserve.

3 Remainder of exposed tissue to be frozen at −70°C for future studies

3. Cryo-preservation of skin specimens.

To preserve skin specimens for future immunohistochemistry or genetic analysis using polymerase chain reaction (PCR) technology those skin specimens, exposed to the test articles and designated for preservation in the protocol, will be quick frozen on a pre-made chuck of frozen optimal cutting temperature (OCT) compound. The tissue will be covered with more OCT compound and frozen by lowering into liquid nitrogen. See also Miller, R.T. Lab Medicine 22, 461 (1991).

4. Processing of skin specimens for histopathology and assay of BrdUrd labeling and proliferation indices

Figure 1

The two skin sections 2a and 2b were placed in two separate cassettes at 6, 24, 48 and 96-h post exposure. In addition to the above skin sections, the pancreas and a section of duodenum were collected at 24, 48, and 96-h post exposure. The abdominal cavity was opened. The stomach was located and approximately 2-3 cm of duodenum, proximal to the stomach, was removed with the pancreas attached. The duodenum and pancreas samples were divided in half with each half going into one of the cassettes along with skin samples 2a and 2b. The cassettes and the remaining carcass were placed in 10% buffered formalin and delivered to Veritas Laboratories, Inc., for histologic processing and histopathologic evaluation on the same day.

The two skin specimens 3 were quick frozen on a pre-made block of frozen optimal cutting temperature (OCT) compound (Tissue Tek®, Miles, Inc., Elkhart, IN) at 6, 24, 48 and 96-h post-exposure. The tissue was spread out, covered with more OCT compound and quick frozen in liquid nitrogen. These specimens, with their labels, were then placed in a freezer (-70°C) and will be retained at ManTech for two years for possible future evaluations.

Q. Epidermal Homogenization: Skin specimen 1 was collected such that excess skin was left attached posterior to the specimen. Each skin specimen was spread on a cold glass plate which was kept on ice. A 1-$cm^2$ segment was scraped from a posterior to anterior direction. The scrapings from each treatment group (4 replicates) were placed in a single tube containing ODC homogenization buffer, pH 7.2 and homogenized for 15 sec twice with a 15 sec interval in between using a polytron tissue homogenizer. The homogenized samples were centrifuged at 15,000 rpm for 30 min and the supernates were divided into two equal aliquots. The samples were frozen a -70°C. On May 24, 1993 all of the samples were packed in dry ice and sent by Federal Express to Dermigen.

R. Statistical Methods: The difference in variance was analyzed in body weights and body weight gains. Body weights and body weight gain data for all treatment groups were compared to the acetone control group using *Dunnett's Test* (Computational Handbook of Statistics, James L. Bruning and B.L. Kintz, 2nd Edition, 1977).

## III. Results

A. Animal Survival: Two mice were accidently killed before the scheduled necropsies. The deaths were not related to the test article exposure.

B. Body Weights: Individual body weights and body weight gains are presented in Table 1. Group mean body weights and body weight gain values are presented in Table 2. There were no statistically significant increases of body weight gains in any of the dosed animals when compared to the acetone treated (negative control) animals (Figure 2).




**Figure 2 - Body Weight Gains**

| Group No. | Group Name |
|---|---|
| 1 | Toluene |
| 2 | Acetone |
| 3 | MSO:Toluene |
| 4 | OLPH, 11.8 µL |
| 5 | OLPH, 23.5 µL |
| 6 | OLPH, 50 µL |
| 7 | OLPH, 100 µL |
| 8 | MSO, 11.8 µL |
| 9 | MSO, 23.5 µL |
| 10 | MSO, 50 µL |
| 11 | MSO, 100 µL |
| 12 | LVD, 11.8 µL |
| 13 | LVD, 23.5 µL |
| 14 | LVD, 33.3 µL |
| 15 | LVD, 100 µL |

| Group No. | Group Name |
|---|---|
| 16 | TPA, 0.2125 nmol |
| 17 | TPA, 0.85 nmol |
| 18 | TPA, 3.4 nmol |
| 19 | TPA, 13.6 nmol |
| 20 | n-Dodecane, 10 mg |
| 21 | n-Dodecane, 25 mg |
| 22 | n-Dodecane, 50 mg |
| 23 | n-Dodecane, 100 mg |
| 24 | BP, 1 mg |
| 25 | BP, 5 mg |
| 26 | BP, 10 mg |
| 27 | BP, 20 mg |

C. Clinical Observations: No treatment-related clinical signs of toxicity, with the exception of dermal irritancy, were observed during the study.

D. Dermal Irritancy: Individual dermal irritancy scoring values are presented in Table 3 with total irritancy scores summarized in Table 4.

E. Necropsy: See Table 5 for observations noted at gross necropsy.

At the 6-h necropsy, 44 mice showed signs of varying degress of skin thickening while 8 mice exhibited thinning areas. Four were scabby, 4 were scaly, and 1 appeared granular. Nineteen skin samples were wrinkled and 8 were flacid or gelatinous. One animal exhibited reddish, bumpy areas.

At the 24-h necropsy, the excised skin from 43 mice showed signs of varying degrees of thickening while 14 had thin areas. Two exhibited bumpy areas, 8 were scaly, 14 were granular, and 9 were scabby. Thirty-five of the mice had wrinkled skin, 7 were gelatinous, and 7 had reddish areas.

At the 48-h necropsy, 21 mice showed signs of skin thickening and 6 mice had thin areas. Forty-nine mice appeared wrinkled, while 6 exhibited scaly areas, 18 were granular, and 17 were scabby. Five mice had reddened areas, 4 mice had raised or swollen areas, and 4 were gelatinous.

At the 96-h necropsy, 41 mice showed signs of varying degrees of skin thickening while 7 had thinning areas. Sixty-two mice exhibited wrinkled skin, while 2 were scaly, 7 were granular, and 12 were scabby. Five of the mice had gelatinous skin and 4 had reddened areas.

F. Protocol Deviations: At the 6-h necropsy, only skin specimen 1 was taken for epidermal homogenization instead of specimens 1, 2a, and 2b as stated in protocol amendment #11. Specimens 2a and 2b were sent to Veritas.

Dosing began at 8:00 instead of 7:00 as stated in protocol amendment #8.

TABLE 1

INDIVIDUAL BODY WEIGHTS AND BODY WEIGHT GAINS (grams)

| Animal Number | Group | Initial Weight | Terminal Weight | Weight Gain |
|---|---|---|---|---|
| 1 | Toluene | 27.7 | 27.3 | -0.4 |
| 2 | Toluene | 30.5 | 30.1 | -0.4 |
| 3 | Toluene | 26.8 | 27.0 | 0.2 |
| 4 | Toluene | 29.6 | 27.6 | -2.0 |
| 5 | Toluene | 25.0 | 27.3 | 2.3 |
| 6 | Toluene | 25.6 | 25.1 | -0.5 |
| 7 | Toluene | 27.4 | 28.2 | 0.8 |
| 8 | Toluene | 24.6 | 27.1 | 2.5 |
| 9 | Toluene | 27.0 | 29.0 | 2.0 |
| 10 | Toluene | 28.8 | 29.6 | 0.8 |
| 11 | Toluene | 28.6 | 29.6 | 1.0 |
| 12 | Toluene | 26.3 | 26.8 | 0.5 |
| 13 | Toluene | 29.2 | 30.8 | 1.6 |
| 14 | Toluene | 25.8 | 27.7 | 1.9 |
| 15 | Toluene | 27.9 | 29.3 | 1.4 |
| 16 | Tóluene | 26.6 | 28.8 | 2.2 |
| 17 | Acetone | 28.7 | 29.7 | 1.0 |
| 18 | Acetone | 26.7 | 30.0 | 3.3 |
| 19 | Acetone | 29.7 | 29.8 | 0.1 |
| 20 | Acetone | 27.7 | 29.6 | 1.9 |
| 21 | Acetone | 27.9 | 28.6 | 0.7 |
| 22 | Acetone | 26.0 | 27.8 | 1.8 |
| 23 | Acetone | 30.6 | 29.5 | -1.1 |
| 24 | Acetone | 27.3 | 27.9 | 0.6 |
| 25 | Acetone | 27.0 | 29.2 | 2.2 |
| 26 | Acetone | 26.4 | 26.7 | 0.3 |
| 27 | Acetone | 26.5 | 27.0 | 0.5 |
| 28 | Acetone | 25.5 | 28.5 | 3.0 |
| 29 | Acetone | 24.8 | 26.5 | 1.7 |
| 30 | Acetone | 29.2 | 27.7 | -1.5 |
| 31 | Acetone | 24.6 | 26.8 | 2.2 |
| 32 | Acetone | 28.3 | 27.8 | -0.5 |
| 33 | MSO:Toluene | 29.3 | 29.9 | 0.6 |
| 34 | MSO:Toluene | 25.5 | 28.0 | 2.5 |
| 35 | MSO:Toluene | 26.6 | 28.2 | 1.6 |
| 36 | MSO:Toluene | 26.0 | 29.3 | 3.3 |
| 37 | MSO:Toluene | 28.1 | 31.2 | 3.1 |
| 38 | MSO:Toluene | 29.0 | 29.5 | 0.5 |
| 39 | MSO:Toluene | 27.6 | 30.8 | 3.2 |
| 40 | MSO:Toluene | 24.0 | 25.1 | 1.1 |
| 41 | MSO:Toluene | 27.0 | 28.5 | 1.5 |
| 42 | MSO:Toluene | 30.0 | 30.8 | 0.8 |
| 43 | MSO:Toluene | 25.0 | 28.9 | 3.9 |
| 44 | MSO:Toluene | 28.5 | 23.9 | -4.6 |
| 45 | MSO:Toluene | 31.2 | 30.8 | -0.4 |
| 46 | MSO:Toluene | 27.3 | 28.4 | 1.1 |
| 47 | MSO:Toluene | 26.7 | 31.6 | 4.9 |
| 48 | MSO:Toluene | 26.4 | 28.5 | 2.1 |
| 49 | OLPH, 11.8 uL | 27.5 | 27.5 | 0.0 |
| 50 | OLPH, 11.8 uL | 28.1 | 27.5 | -0.6 |
| 51 | OLPH, 11.8 uL | 26.5 | 25.4 | -1.1 |
| 52 | OLPH, 11.8 uL | 24.9 | 25.9 | 1.0 |
| 53 | OLPH, 11.8 uL | 29.6 | 30.4 | 0.8 |
| 54 | OLPH, 11.8 uL | 28.8 | 30.3 | 1.5 |
| 55 | OLPH, 11.8 uL | 25.2 | 27.1 | 1.9 |
| 56 | OLPH, 11.8 uL | 27.0 | 27.3 | 0.3 |
| 57 | OLPH, 11.8 uL | 23.5 | 26.7 | 3.2 |
| 58 | OLPH, 11.8 uL | 26.9 | 29.3 | 2.4 |
| 59 | OLPH, 11.8 uL | 30.8 | 29.5 | -1.3 |
| 60 | OLPH, 11.8 uL | 25.7 | 26.8 | 1.1 |
| 61 | OLPH, 11.8 uL | 26.3 | 27.6 | 1.3 |
| 62 | OLPH, 11.8 uL | 29.4 | 29.2 | -0.2 |
| 63 | OLPH, 11.8 uL | 28.7 | 31.0 | 2.3 |
| 64 | OLPH, 11.8 uL | 27.6 | 27.3 | -0.3 |

TABLE 1

INDIVIDUAL BODY WEIGHTS AND BODY WEIGHT GAINS (grams)

| Animal Number | Group | Initial Weight | Terminal Weight | Weight Gain |
|---|---|---|---|---|
| 65 | OLPN, 23.5 uL | 27.5 | 29.4 | 1.9 |
| 66 | OLPN, 23.5 uL | 28.4 | 30.4 | 2.0 |
| 67 | OLPN, 23.5 uL | 27.3 | 30.3 | 3.0 |
| 68 | OLPN, 23.5 uL | 24.7 | 28.9 | 4.2 |
| 69 | OLPN, 23.5 uL | 30.4 | 32.0 | 1.6 |
| 70 | OLPN, 23.5 uL | 23.8 | 25.5 | 1.7 |
| 71 | OLPN, 23.5 uL | 25.3 | 25.6 | 0.3 |
| 72 | OLPN, 23.5 uL | 29.4 | 32.5 | 3.1 |
| 73 | OLPN, 23.5 uL | 28.9 | 30.1 | 1.2 |
| 74 | OLPN, 23.5 uL | 25.9 | 27.6 | 1.7 |
| 75 | OLPN, 23.5 uL | 26.7 | 27.5 | 0.8 |
| 76 | OLPN, 23.5 uL | 26.3 | 28.6 | 2.3 |
| 77 | OLPN, 23.5 uL | 27.1 | 27.2 | 0.1 |
| 78 | OLPN, 23.5 uL | 29.7 | 31.5 | 1.8 |
| 79 | OLPN, 23.5 uL | 27.9 | 30.8 | 2.9 |
| 80 | OLPN, 23.5 uL | 26.8 | 28.2 | 1.4 |
| 81 | OLPN, 50 uL | 26.1 | 28.0 | 1.9 |
| 82 | OLPN, 50 uL | 23.9 | 25.1 | 1.2 |
| 83 | OLPN, 50 uL | 28. | 31.4 | 3.3 |
| 84 | OLPN, 50 uL | 28.9 | 27.7 | -1.2 |
| 85 | OLPN, 50 uL | 26.5 | 28.2 | 1.7 |
| 86 | OLPN, 50 uL | 28.4 | 28.0 | -0.4 |
| 87 | OLPN, 50 uL | 27.2 | 30.1 | 2.9 |
| 88 | OLPN, 50 uL | 30.1 | 31.6 | 1.5 |
| 89 | OLPN, 50 uL | 25.7 | 27.0 | 1.3 |
| 90 | OLPN, 50 uL | 25.1 | 26.4 | 1.3 |
| 91 | OLPN, 50 uL | 30.9 | 30.3 | -0.6 |
| 92 | OLPN, 50 uL | 29.4 | 31.5 | 2.1 |
| 93 | OLPN, 50 uL | 26.8 | 27.7 | 0.9 |
| 94 | OLPN, 50 uL | 25.3 | 26.9 | 1.6 |
| 95 | OLPN, 50 uL | 27.4 | 29.2 | 1.8 |
| 96 | OLPN, [illegible] | 27.8 | 30.6 | 2.8 |
| 97 | OLPN, [illegible] uL | 27.0 | 28.1 | 1.1 |
| 98 | OLPN, [illegible] uL | 27.8 | 29.0 | 1.2 |
| 99 | OLPN, 100 uL | 28.3 | 28.8 | 0.5 |
| 100 | OLPN, 100 uL | 24.8 | 25.8 | 1.0 |
| 101 | OLPN, 100 uL | 26.3 | 27.4 | 1.1 |
| 102 | OLPN, 100 uL | 24.3 | 27.4 | 3.1 |
| 103 | OLPN, 100 uL | 30.4 | 30.7 | 0.3 |
| 104 | OLPN, 100 uL | 26.9 | 28.0 | 1.1 |
| 105 | OLPN, 100 uL | 27.4 | 28.5 | 1.1 |
| 106 | OLPN, 100 uL | 25.5 | 25.9 | 0.4 |
| 107 | OLPN, 100 uL | 30.1 | 30.4 | 0.3 |
| 108 | OLPN, 100 uL | 29.2 | 29.4 | 0.2 |
| 109 | OLPN, 100 uL | 29.0 | 29.3 | 0.3 |
| 110 | OLPN, 100 uL | 25.8 | 26.0 | 0.2 |
| 111 | OLPN, 100 uL | 27.9 | Died | Died |
| 112 | OLPN, 100 uL | 26.6 | 28.2 | 1.6 |
| 113 | MSO, 11.8 uL | 25.7 | 26.8 | 1.1 |
| 114 | MSO, 11.8 uL | 26.8 | 29.9 | 3.1 |
| 115 | MSO, 11.8 uL | 28.1 | 27.3 | -0.8 |
| 116 | MSO, 11.8 uL | 26.5 | 28.1 | 1.6 |
| 117 | MSO, 11.8 uL | 26.1 | 26.3 | 0.2 |
| 118 | MSO, 11.8 uL | 30.2 | 31.8 | 1.6 |
| 119 | MSO, 11.8 uL | 31.1 | 29.5 | -1.6 |
| 120 | MSO, 11.8 uL | 28.4 | 31.9 | 3.5 |
| 121 | MSO, 11.8 uL | 24.7 | 27.4 | 2.7 |
| 122 | MSO, 11.8 uL | 29.0 | 29.3 | 0.3 |
| 123 | MSO, 11.8 uL | 27.3 | 28.0 | 0.7 |
| 124 | MSO, 11.8 uL | 27.6 | 28.6 | 1.0 |
| 125 | MSO, 11.8 uL | 27.1 | 28.9 | 1.8 |
| 126 | MSO, 11.8 uL | 25.7 | 25.9 | 0.2 |
| 127 | MSO, 11.8 uL | 23.9 | 24.5 | 0.6 |
| 128 | MSO, 11.8 uL | 29.5 | 30.2 | 0.7 |

TABLE 1

INDIVIDUAL BODY WEIGHTS AND BODY WEIGHT GAINS (grams)

| Animal Number | Group | Initial Weight | Terminal Weight | Weight Gain |
|---|---|---|---|---|
| 129 | NSO, 23.5 uL | 27.4 | 28.3 | 0.9 |
| 130 | NSO, 23.5 uL | 25.9 | 28.9 | 3.0 |
| 131 | NSO, 23.5 uL | 29.6 | 29.8 | 0.2 |
| 132 | NSO, 23.5 uL | 28.7 | 28.9 | 0.2 |
| 133 | NSO, 23.5 uL | 24.0 | 25.6 | 1.6 |
| 134 | NSO, 23.5 uL | 30.5 | 29.6 | -0.9 |
| 135 | NSO, 23.5 uL | 28.2 | 29.8 | 1.6 |
| 136 | NSO, 23.5 uL | 26.7 | 29.2 | 2.5 |
| 137 | NSO, 23.5 uL | 25.5 | 27.6 | 2.1 |
| 138 | NSO, 23.5 uL | 26.6 | 27.7 | 1.1 |
| 139 | NSO, 23.5 uL | 25.1 | 26.8 | 1.7 |
| 140 | NSO, 23.5 uL | 30.1 | 30.4 | 0.3 |
| 141 | NSO, 23.5 uL | 27.1 | 27.7 | 0.6 |
| 142 | NSO, 23.5 uL | 26.4 | 28.2 | 1.8 |
| 143 | NSO, 23.5 uL | 27.6 | 29.1 | 1.5 |
| 144 | NSO, 23.5 uL | 28.4 | 27.6 | -0.8 |
| 145 | NSO, 50 uL | 27.6 | 28.0 | 0.4 |
| 146 | NSO, 50 uL | 29.3 | 27.3 | -2.0 |
| 147 | NSO, 50 uL | 26.5 | 27.7 | 1.2 |
| 148 | NSO, 50 uL | 28.6 | 29.9 | 1.3 |
| 149 | NSO, 50 uL | 28.8 | 29.5 | 0.7 |
| 150 | NSO, 50 uL | 27.1 | 28.7 | 1.6 |
| 151 | NSO, 50 uL | 27.5 | 28.6 | 1.1 |
| 152 | NSO, 50 uL | 25.2 | 26.9 | 1.7 |
| 153 | NSO, 50 uL | 26.9 | 26.6 | -0.3 |
| 154 | NSO, 50 uL | 26.3 | 26.4 | 0.1 |
| 155 | NSO, 50 uL | 24.5 | 29.4 | 4.9 |
| 156 | NSO, 50 uL | 27.9 | 27.1 | -0.8 |
| 157 | NSO, 50 uL | 25.2 | 27.4 | 2.2 |
| 158 | NSO, 50 uL | 30.6 | 29.5 | -1.1 |
| 159 | NSO, 50 uL | 25.7 | 29.2 | 3.5 |
| 160 | NSO, 50 uL | 30.2 | 30.6 | 0.4 |
| 161 | NSO, 100 uL | 30.7 | 30.6 | -0.1 |
| 162 | NSO, 100 uL | 25.8 | 28.5 | 2.7 |
| 163 | NSO, 100 uL | 28.7 | 29.1 | 0.4 |
| 164 | NSO, 100 uL | 27.3 | 27.5 | 0.2 |
| 165 | NSO, 100 uL | 27.7 | 30.0 | 2.3 |
| 166 | NSO, 100 uL | 29.4 | 30.8 | 1.4 |
| 167 | NSO, 100 uL | 26.9 | 29.0 | 2.1 |
| 168 | NSO, 100 uL | 25.2 | 24.0 | -1.2 |
| 169 | NSO, 100 uL | 29.9 | 31.2 | 1.3 |
| 170 | NSO, 100 uL | 26.3 | 27.4 | 1.1 |
| 171 | NSO, 100 uL | 26.7 | 26.9 | 0.2 |
| 172 | NSO, 100 uL | 28.8 | 28.6 | -0.2 |
| 173 | NSO, 100 uL | 24.1 | 27.2 | 3.1 |
| 174 | NSO, 100 uL | 25.0 | 28.0 | 3.0 |
| 175 | NSO, 100 uL | 27.0 | 28.4 | 1.4 |
| 176 | NSO, 100 uL | 28.0 | 29.6 | 1.6 |
| 177 | LVD, 11.8 uL | 29.2 | 28.2 | -1.0 |
| 178 | LVD, 11.8 uL | 31.2 | 31.8 | 0.6 |
| 179 | LVD, 11.8 uL | 27.6 | 27.1 | -0.5 |
| 180 | LVD, 11.8 uL | 25.6 | 27.9 | 2.3 |
| 181 | LVD, 11.8 uL | 26.4 | 26.4 | 0.0 |
| 182 | LVD, 11.8 uL | 29.7 | 29.2 | -0.5 |
| 183 | LVD, 11.8 uL | 27.1 | 26.4 | -0.7 |
| 184 | LVD, 11.8 uL | 28.8 | 29.1 | 0.3 |
| 185 | LVD, 11.8 uL | 28.7 | 30.7 | 2.0 |
| 186 | LVD, 11.8 uL | 26.1 | 26.7 | 0.6 |
| 187 | LVD, 11.8 uL | 27.2 | 27.6 | 0.4 |
| 188 | LVD, 11.8 uL | 25.0 | 25.7 | 0.7 |
| 189 | LVD, 11.8 uL | 26.0 | 25.8 | -0.2 |
| 190 | LVD, 11.8 uL | 23.5 | 26.2 | 2.7 |
| 191 | LVD, 11.8 uL | 27.9 | 27.6 | -0.3 |
| 192 | LVD, 11.8 uL | 26.8 | 30.1 | 3.3 |

TABLE 1

INDIVIDUAL BODY WEIGHTS AND BODY WEIGHT GAINS (grams)

| Animal Number | Group | Initial Weight | Terminal Weight | Weight Gain |
|---|---|---|---|---|
| 193 | LVD, 23.5 uL | 28.7 | 30.4 | 1.7 |
| 194 | LVD, 23.5 uL | 27.2 | 28.7 | 1.5 |
| 195 | LVD, 23.5 uL | 25.7 | 26.6 | 0.9 |
| 196 | LVD, 23.5 uL | 29.4 | 28.4 | -1.0 |
| 197 | LVD, 23.5 uL | 25.3 | 29.3 | 4.0 |
| 198 | LVD, 23.5 uL | 25.1 | 28.4 | 3.3 |
| 199 | LVD, 23.5 uL | 28.5 | 27.7 | -0.8 |
| 200 | LVD, 23.5 uL | 27.2 | 32.2 | 5.0 |
| 201 | LVD, 23.5 uL | 27.9 | 28.1 | 0.2 |
| 202 | LVD, 23.5 uL | 26.4 | 28.0 | 1.6 |
| 203 | LVD, 23.5 uL | 30.1 | 29.8 | -0.3 |
| 204 | LVD, 23.5 uL | 31.2 | 33.6 | 2.4 |
| 205 | LVD, 23.5 uL | 26.7 | 29.0 | 2.3 |
| 206 | LVD, 23.5 uL | 27.6 | 29.3 | 1.7 |
| 207 | LVD, 23.5 uL | 24.5 | 25.5 | 1.0 |
| 208 | LVD, 23.5 uL | 26.5 | 26.6 | 0.1 |
| 209 | LVD, 33.3 uL | 28.2 | 28.9 | 0.7 |
| 503 | LVD, 33.3 uL | 24.6 | 33.6 | 9.0 |
| 211 | LVD, 33.3 uL | 26.6 | 27.7 | 1.1 |
| 212 | LVD, 33.3 uL | 27.1 | 30.2 | 3.1 |
| 213 | LVD, 33.3 uL | 25.6 | 27.4 | 1.8 |
| 214 | LVD, 33.3 uL | 25.7 | 27.4 | 1.7 |
| 215 | LVD, 33.3 uL | 26.0 | 27.5 | 1.5 |
| 216 | LVD, 33.3 uL | 27.7 | 29.0 | 1.3 |
| 217 | LVD, 33.3 uL | 25.0 | 26.7 | 1.7 |
| 218 | LVD, 33.3 uL | 28.3 | 29.6 | 1.3 |
| 219 | LVD, 33.3 uL | 27.4 | 29.0 | 1.6 |
| 220 | LVD, 33.3 uL | 29.1 | 29.2 | 0.1 |
| 221 | LVD, 33.3 uL | 31.4 | 32.1 | 0.7 |
| 222 | LVD, 33.3 uL | 29.4 | 30.0 | 0.6 |
| 223 | LVD, 33.3 uL | 29.8 | Died | Died |
| 224 | LVD, 33.3 uL | 26.9 | 27.2 | 0.3 |
| 225 | LVD, 100 uL | 25.0 | 25.7 | 0.7 |
| 226 | LVD, 100 uL | 29.5 | 30.4 | 0.9 |
| 227 | LVD, 100 uL | 30.2 | 30.0 | -0.2 |
| 228 | LVD, 100 uL | 25.6 | 29.3 | 3.7 |
| 229 | LVD, 100 uL | 26.2 | 28.3 | 2.1 |
| 230 | LVD, 100 uL | 28.4 | 34.7 | 6.3 |
| 231 | LVD, 100 uL | 27.8 | 27.9 | 0.1 |
| 232 | LVD, 100 uL | 28.1 | 30.8 | 2.7 |
| 233 | LVD, 100 uL | 26.8 | 28.2 | 1.4 |
| 234 | LVD, 100 uL | 24.0 | 25.5 | 1.5 |
| 235 | LVD, 100 uL | 27.4 | 28.9 | 1.5 |
| 236 | LVD, 100 uL | 31.3 | 31.5 | 0.2 |
| 237 | LVD, 100 uL | 26.5 | 29.0 | 2.5 |
| 238 | LVD, 100 uL | 26.0 | 25.8 | -0.2 |
| 239 | LVD, 100 uL | 27.2 | 26.4 | -0.8 |
| 240 | LVD, 100 uL | 29.0 | 30.0 | 1.0 |
| 241 | TPA, 0.2125 nmol | 27.4 | 28.3 | 0.9 |
| 242 | TPA, 0.2125 nmol | 27.5 | 29.9 | 2.4 |
| 243 | TPA, 0.2125 nmol | 27.9 | 28.2 | 0.3 |
| 244 | TPA, 0.2125 nmol | 30.7 | 29.7 | -1.0 |
| 245 | TPA, 0.2125 nmol | 26.4 | 25.4 | -1.0 |
| 246 | TPA, 0.2125 nmol | 24.0 | 27.8 | 3.8 |
| 247 | TPA, 0.2125 nmol | 24.8 | 27.4 | 2.6 |
| 248 | TPA, 0.2125 nmol | 26.7 | 29.6 | 2.9 |
| 249 | TPA, 0.2125 nmol | 29.3 | 29.5 | 0.2 |
| 250 | TPA, 0.2125 nmol | 28.9 | 27.8 | -1.1 |
| 251 | TPA, 0.2125 nmol | 27.0 | 29.6 | 2.6 |
| 252 | TPA, 0.2125 nmol | 28.7 | 29.8 | 1.1 |
| 253 | TPA, 0.2125 nmol | 29.8 | 28.9 | -0.9 |
| 254 | TPA, 0.2125 nmol | 25.7 | 26.6 | 0.9 |
| 255 | TPA, 0.2125 nmol | 25.4 | 26.9 | 1.5 |
| 456 | TPA, 0.2125 nmol | 26.6 | 27.9 | 1.3 |

TABLE 1

INDIVIDUAL BODY WEIGHTS AND BODY WEIGHT GAINS (grams)

| Animal Number | Group | Initial Weight | Terminal Weight | Weight Gain |
|---|---|---|---|---|
| 257 | TPA, 0.85 nmol | 26.2 | 26.1 | -0.1 |
| 258 | TPA, 0.85 nmol | 27.2 | 27.9 | 0.7 |
| 259 | TPA, 0.85 nmol | 25.2 | 27.2 | 2.0 |
| 260 | TPA, 0.85 nmol | 28.7 | 26.4 | -2.3 |
| 261 | TPA, 0.85 nmol | 26.9 | 26.0 | -0.9 |
| 262 | TPA, 0.85 nmol | 29.5 | 32.5 | 3.0 |
| 263 | TPA, 0.85 nmol | 27.7 | 29.9 | 2.2 |
| 264 | TPA, 0.85 nmol | 25.6 | 26.8 | 1.2 |
| 265 | TPA, 0.85 nmol | 27.0 | 27.8 | 0.8 |
| 266 | TPA, 0.85 nmol | 30.1 | 31.9 | 1.8 |
| 267 | TPA, 0.85 nmol | 26.5 | 27.7 | 1.2 |
| 268 | TPA, 0.85 nmol | 29.0 | 30.3 | 1.3 |
| 269 | TPA, 0.85 nmol | 30.4 | 29.7 | -0.7 |
| 270 | TPA, 0.85 nmol | 28.2 | 30.7 | 2.5 |
| 271 | TPA, 0.85 nmol | 25.9 | 28.2 | 2.3 |
| 272 | TPA, 0.85 nmol | 24.3 | 27.2 | 2.9 |
| 273 | TPA, 3.4 nmol | 25.9 | 27.7 | 1.8 |
| 274 | TPA, 3.4 nmol | 31.0 | 32.0 | 1.0 |
| 275 | TPA, 3.4 nmol | 29.3 | 29.2 | -0.1 |
| 276 | TPA, 3.4 nmol | 29.1 | 28.5 | -0.6 |
| 277 | TPA, 3.4 nmol | 28.1 | 26.7 | -1.4 |
| 278 | TPA, 3.4 nmol | 30.1 | 29.3 | -0.8 |
| 279 | TPA, 3.4 nmol | 27.2 | 29.1 | 1.9 |
| 280 | TPA, 3.4 nmol | 25.2 | 27.7 | 2.5 |
| 281 | TPA, 3.4 nmol | 28.4 | 27.9 | -0.5 |
| 282 | TPA, 3.4 nmol | 26.6 | 27.4 | 0.8 |
| 283 | TPA, 3.4 nmol | 27.8 | 29.2 | 1.4 |
| 284 | TPA, 3.4 nmol | 24.8 | 25.1 | 0.3 |
| 285 | TPA, 3.4 nmol | 27.1 | 27.0 | -0.1 |
| 286 | TPA, 3.4 nmol | 26.9 | 27.6 | 0.7 |
| 287 | TPA, 3.4 nmol | 24.2 | 25.7 | 1.5 |
| 288 | TPA, 3.4 nmol | 26.3 | 28.2 | 1.9 |
| 289 | TPA, 13.6 nmol | 30.6 | 30.0 | -0.6 |
| 290 | TPA, 13.6 nmol | 26.7 | 27.9 | 1.2 |
| 291 | TPA, 13.6 nmol | 26.0 | 26.9 | 0.9 |
| 292 | TPA, 13.6 nmol | 29.7 | 32.1 | 2.4 |
| 293 | TPA, 13.6 nmol | 25.6 | 28.2 | 2.6 |
| 294 | TPA, 13.6 nmol | 27.4 | 28.4 | 1.0 |
| 295 | TPA, 13.6 nmol | 29.0 | 30.1 | 1.1 |
| 296 | TPA, 13.6 nmol | 28.5 | 29.2 | 0.7 |
| 297 | TPA, 13.6 nmol | 27.1 | 29.3 | 2.2 |
| 298 | TPA, 13.6 nmol | 25.2 | 27.9 | 2.7 |
| 299 | TPA, 13.6 nmol | 28.2 | 25.2 | -3.0 |
| 300 | TPA, 13.6 nmol | 26.4 | 25.6 | -0.8 |
| 301 | TPA, 13.6 nmol | 29.3 | 29.8 | 0.5 |
| 302 | TPA, 13.6 nmol | 27.8 | 30.7 | 2.9 |
| 303 | TPA, 13.6 nmol | 26.2 | 27.1 | 0.9 |
| 304 | TPA, 13.6 nmol | 23.9 | 24.8 | 0.9 |
| 305 | Dodecane, 10 mg/mL | 25.9 | 25.5 | -0.4 |
| 306 | Dodecane, 10 mg/mL | 28.4 | 28.5 | 0.1 |
| 307 | Dodecane, 10 mg/mL | 28.9 | 29.2 | 0.3 |
| 308 | Dodecane, 10 mg/mL | 27.8 | 29.0 | 1.2 |
| 309 | Dodecane, 10 mg/mL | 29.9 | 29.5 | -0.4 |
| 310 | Dodecane, 10 mg/mL | 29.2 | 28.8 | -0.4 |
| 311 | Dodecane, 10 mg/mL | 23.7 | 25.5 | 1.8 |
| 312 | Dodecane, 10 mg/mL | 27.0 | 31.4 | 4.4 |
| 313 | Dodecane, 10 mg/mL | 26.0 | 24.6 | -1.4 |
| 314 | Dodecane, 10 mg/mL | 28.1 | 31.2 | 3.1 |
| 315 | Dodecane, 10 mg/mL | 25.2 | 30.2 | 5.0 |
| 316 | Dodecane, 10 mg/mL | 26.5 | 27.2 | 0.7 |
| 317 | Dodecane, 10 mg/mL | 27.2 | 29.4 | 2.2 |
| 318 | Dodecane, 10 mg/mL | 25.2 | 26.8 | 1.6 |
| 319 | Dodecane, 10 mg/mL | 30.9 | 30.9 | 0.0 |
| 320 | Dodecane, 10 mg/mL | 26.7 | 28.2 | 1.5 |

TABLE 1

INDIVIDUAL BODY WEIGHTS AND BODY WEIGHT GAINS (grams)

| Animal Number | Group | Initial Weight | Terminal Weight | Weight Gain |
|---|---|---|---|---|
| 321 | Dodecane, 25 mg/mL | 28.8 | 28.9 | 0.1 |
| 322 | Dodecane, 25 mg/mL | 27.4 | 28.5 | 1.1 |
| 451 | Dodecane, 25 mg/mL | 29.8 | 30.2 | 0.4 |
| 324 | Dodecane, 25 mg/mL | 25.4 | 26.1 | 0.7 |
| 325 | Dodecane, 25 mg/mL | 26.2 | 29.8 | 3.6 |
| 326 | Dodecane, 25 mg/mL | 24.3 | 27.2 | 2.9 |
| 327 | Dodecane, 25 mg/mL | 29.2 | 29.6 | 0.4 |
| 328 | Dodecane, 25 mg/mL | 27.7 | 28.0 | 0.3 |
| 329 | Dodecane, 25 mg/mL | 28.0 | 31.8 | 3.8 |
| 330 | Dodecane, 25 mg/mL | 26.6 | 27.7 | 1.1 |
| 331 | Dodecane, 25 mg/mL | 28.3 | 29.3 | 1.0 |
| 332 | Dodecane, 25 mg/mL | 30.6 | 32.3 | 1.7 |
| 333 | Dodecane, 25 mg/mL | 27.2 | 27.9 | 0.7 |
| 334 | Dodecane, 25 mg/mL | 26.9 | 27.6 | 0.7 |
| 335 | Dodecane, 25 mg/mL | 25.7 | 26.3 | 0.6 |
| 336 | Dodecane, 25 mg/mL | 24.7 | 28.3 | 3.6 |
| 337 | Dodecane, 50 mg/mL | 29.4 | 29.3 | -0.1 |
| 338 | Dodecane, 50 mg/mL | 24.6 | 27.3 | 2.7 |
| 339 | Dodecane, 50 mg/mL | 26.6 | 28.3 | 1.7 |
| 340 | Dodecane, 50 mg/mL | 27.5 | 28.7 | 1.2 |
| 341 | Dodecane, 50 mg/mL | 23.7 | 25.9 | 2.2 |
| 342 | Dodecane, 50 mg/mL | 25.8 | 27.5 | 1.7 |
| 343 | Dodecane, 50 mg/mL | 25.7 | 27.7 | 2.0 |
| 344 | Dodecane, 50 mg/mL | 28.8 | 29.1 | 0.3 |
| 345 | Dodecane, 50 mg/mL | 28.6 | 28.9 | 0.3 |
| 346 | Dodecane, 50 mg/mL | 26.7 | 27.4 | 0.7 |
| 347 | Dodecane, 50 mg/mL | 29.7 | 29.0 | -0.7 |
| 348 | Dodecane, 50 mg/mL | 27.1 | 28.0 | 0.9 |
| 349 | Dodecane, 50 mg/mL | 27.6 | 27.6 | 0.0 |
| 350 | Dodecane, 50 mg/mL | 26.0 | 28.8 | 2.8 |
| 351 | Dodecane, 50 mg/mL | 31.2 | 26.8 | -4.4 |
| 352 | Dodecane, 50 mg/mL | 28.0 | 27.5 | -0.5 |
| 353 | Dodecane, 100 mg/mL | 27.9 | 29.8 | 1.9 |
| 354 | Dodecane, 100 mg/mL | 26.6 | 26.7 | 0.1 |
| 355 | Dodecane, 100 mg/mL | 27.2 | 27.8 | 0.6 |
| 356 | Dodecane, 100 mg/mL | 28.7 | 30.5 | 1.8 |
| 357 | Dodecane, 100 mg/mL | 26.0 | 26.7 | 0.7 |
| 358 | Dodecane, 100 mg/mL | 30.2 | 30.7 | 0.5 |
| 517 | Dodecane, 100 mg/mL | 23.9 | 26.4 | 2.5 |
| 360 | Dodecane, 100 mg/mL | 25.8 | 28.1 | 2.3 |
| 361 | Dodecane, 100 mg/mL | 29.2 | 29.4 | 0.2 |
| 362 | Dodecane, 100 mg/mL | 25.4 | 28.8 | 3.4 |
| 363 | Dodecane, 100 mg/mL | 28.9 | 30.0 | 1.1 |
| 364 | Dodecane, 100 mg/mL | 27.4 | 29.2 | 1.8 |
| 365 | Dodecane, 100 mg/mL | 25.1 | 26.4 | 1.3 |
| 366 | Dodecane, 100 mg/mL | 30.4 | 31.4 | 1.0 |
| 367 | Dodecane, 100 mg/mL | 26.9 | 28.0 | 1.1 |
| 368 | Dodecane, 100 mg/mL | 27.8 | 27.0 | -0.8 |
| 369 | BP, 1 mg/mL | 25.0 | 26.3 | 1.3 |
| 370 | BP, 1 mg/mL | 25.7 | 30.7 | 5.0 |
| 371 | BP, 1 mg/mL | 27.5 | 27.9 | 0.4 |
| 372 | BP, 1 mg/mL | 26.5 | 28.6 | 2.1 |
| 373 | BP, 1 mg/mL | 27.9 | 29.4 | 1.5 |
| 374 | BP, 1 mg/mL | 25.4 | 27.0 | 1.6 |
| 375 | BP, 1 mg/mL | 29.5 | 31.5 | 2.0 |
| 376 | BP, 1 mg/mL | 29.7 | 30.0 | 0.3 |
| 377 | BP, 1 mg/mL | 27.9 | 28.7 | 0.8 |
| 378 | BP, 1 mg/mL | 30.3 | 32.9 | 2.6 |
| 379 | BP, 1 mg/mL | 27.0 | 27.6 | 0.6 |
| 380 | BP, 1 mg/mL | 28.7 | 27.8 | -0.9 |
| 381 | BP, 1 mg/mL | 26.3 | 28.3 | 2.0 |
| 382 | BP, 1 mg/mL | 28.8 | 28.0 | -0.8 |
| 383 | BP, 1 mg/mL | 26.7 | 27.1 | 0.4 |
| 384 | BP, 1 mg/mL | 24.5 | 28.1 | 3.6 |

TABLE 1

INDIVIDUAL BODY WEIGHTS AND BODY WEIGHT GAINS (grams)

| Animal Number | Group | Initial Weight | Terminal Weight | Weight Gain |
|---|---|---|---|---|
| 385 | BP, 5 mg/mL | 28.4 | 27.9 | -0.5 |
| 386 | BP, 5 mg/mL | 25.9 | 27.7 | 1.8 |
| 387 | BP, 5 mg/mL | 25.0 | 27.2 | 2.2 |
| 388 | BP, 5 mg/mL | 27.0 | 28.5 | 1.5 |
| 389 | BP, 5 mg/mL | 30.1 | 30.8 | 0.7 |
| 390 | BP, 5 mg/mL | 25.4 | 26.1 | 0.7 |
| 391 | BP, 5 mg/mL | 29.1 | 28.6 | -0.5 |
| 392 | BP, 5 mg/mL | 29.6 | 28.1 | -1.5 |
| 393 | BP, 5 mg/mL | 26.8 | 28.9 | 2.1 |
| 394 | BP, 5 mg/mL | 23.9 | 25.0 | 1.1 |
| 395 | BP, 5 mg/mL | 27.5 | 27.3 | -0.2 |
| 396 | BP, 5 mg/mL | 27.5 | 28.8 | 1.3 |
| 397 | BP, 5 mg/mL | 27.9 | 28.0 | 0.1 |
| 398 | BP, 5 mg/mL | 26.7 | 26.3 | -0.4 |
| 399 | BP, 5 mg/mL | 26.3 | 30.9 | 4.6 |
| 400 | BP, 5 mg/mL | 30.6 | 32.5 | 1.9 |
| 401 | BP, 10 mg/mL | 26.8 | 30.8 | 4.0 |
| 402 | BP, 10 mg/mL | 25.9 | 30.1 | 4.2 |
| 403 | BP, 10 mg/mL | 27.1 | 28.8 | 1.7 |
| 404 | BP, 10 mg/mL | 28.8 | 28.9 | 0.1 |
| 405 | BP, 10 mg/mL | 27.4 | 29.0 | 1.6 |
| 406 | BP, 10 mg/mL | 26.1 | 26.7 | 0.6 |
| 407 | BP, 10 mg/mL | 29.3 | 28.2 | -1.1 |
| 408 | BP, 10 mg/mL | 24.3 | 26.4 | 2.1 |
| 409 | BP, 10 mg/mL | 25.5 | 26.6 | 1.1 |
| 410 | BP, 10 mg/mL | 29.7 | 27.5 | -2.2 |
| 411 | BP, 10 mg/mL | 24.7 | 27.4 | 2.7 |
| 412 | BP, 10 mg/mL | 30.8 | 33.4 | 2.6 |
| 413 | BP, 10 mg/mL | 28.3 | 27.4 | -0.9 |
| 414 | BP, 10 mg/mL | 28.1 | 30.0 | 1.9 |
| 415 | BP, 10 mg/mL | 26.6 | 28.2 | 1.6 |
| 416 | BP, 10 mg/mL | 27.7 | 29.3 | 1.6 |
| 417 | BP, 20 mg/mL | 26.2 | 27.2 | 1.0 |
| 418 | BP, 20 mg/mL | 26.8 | 28.3 | 1.5 |
| 419 | BP, 20 mg/mL | 23.8 | 26.4 | 2.6 |
| 420 | BP, 20 mg/mL | 29.6 | 28.9 | -0.7 |
| 421 | BP, 20 mg/mL | 28.9 | 28.0 | -0.9 |
| 422 | BP, 20 mg/mL | 30.5 | 27.3 | -3.2 |
| 423 | BP, 20 mg/mL | 27.2 | 28.9 | 1.7 |
| 424 | BP, 20 mg/mL | 26.5 | 27.6 | 1.1 |
| 425 | BP, 20 mg/mL | 29.2 | 28.9 | -0.3 |
| 426 | BP, 20 mg/mL | 25.0 | 26.5 | 1.5 |
| 427 | BP, 20 mg/mL | 25.7 | 27.6 | 1.9 |
| 428 | BP, 20 mg/mL | 27.4 | 28.2 | 0.8 |
| 429 | BP, 20 mg/mL | 27.6 | 26.9 | -0.7 |
| 430 | BP, 20 mg/mL | 28.0 | 29.6 | 1.6 |
| 431 | BP, 20 mg/mL | 28.7 | 29.7 | 1.0 |
| 432 | BP, 20 mg/mL | 25.4 | 28.9 | 3.5 |

TABLE 2

Mean Body Weights and Body Weight Gains

| Group | Initial Weight | Terminal Weight | Weight Gain |
|---|---|---|---|
| Toluene | 27.3 ± 1.7 | 28.4 ± 1.5 | 1.0 ± 1.2 |
| Acetone | 27.3 ± 1.7 | 28.3 ± 1.2 | 1.0 ± 1.4 |
| MSO:Toluene | 27.4 ± 1.9 | 29.0 ± 2.1 | 1.6 ± 2.2 |
| OLPN, 11.8 uL | 27.3 ± 1.9 | 28.1 ± 1.7 | 0.8 ± 1.3 |
| OLPN, 23.5 uL | 27.3 ± 1.8 | 29.1 ± 2.1 | 1.9 ± 1.1 |
| OLPN, 50 uL | 27.4 ± 1.9 | 28.7 ± 2.0 | 1.4 ± 1.2 |
| OLPN, 100 uL | 27.3 ± 1.8 | 28.2 ± 1.5 | 0.9 ± 0.8 |
| MSO, 11.8 uL | 27.4 ± 2.0 | 28.4 ± 2.0 | 1.0 ± 1.3 |
| MSO, 23.5 uL | 27.4 ± 1.8 | 28.5 ± 1.3 | 1.1 ± 1.1 |
| MSO, 50 uL | 27.4 ± 1.8 | 28.3 ± 1.3 | 0.9 ± 1.7 |
| MSO, 100 uL | 27.3 ± 1.9 | 28.6 ± 1.8 | 1.2 ± 1.2 |
| LVD, 11.8 uL | 27.3 ± 1.9 | 27.9 ± 1.8 | 0.6 ± 1.3 |
| LVD, 23.5 uL | 27.4 ± 1.9 | 28.9 ± 2.0 | 1.5 ± 1.7 |
| LVD, 33.3 uL | 27.4 ± 1.9 | 29.0 ± 1.9 | 1.8 ± 2.1 |
| LVD, 100 uL | 27.4 ± 1.9 | 28.9 ± 2.4 | 1.5 ± 1.8 |
| TPA, 0.2125 nmol | 27.3 ± 1.9 | 28.3 ± 1.3 | 1.0 ± 1.5 |
| TPA, 0.85 nmol | 27.4 ± 1.8 | 28.5 ± 2.1 | 1.1 ± 1.5 |
| TPA, 3.4 nmol | 27.4 ± 1.9 | 28.0 ± 1.6 | 0.6 ± 1.1 |
| TPA, 13.6 nmol | 27.4 ± 1.8 | 28.3 ± 2.1 | 1.0 ± 1.5 |
| Dodecane, 10 mg/mL | 27.3 ± 1.9 | 28.5 ± 2.1 | 1.2 ± 1.8 |
| Dodecane, 25 mg/mL | 27.3 ± 1.8 | 28.7 ± 1.7 | 1.4 ± 1.3 |
| Dodecane, 50 mg/mL | 27.3 ± 2.0 | 28.0 ± 0.9 | 0.7 ± 1.7 |
| Dodecane, 100 mg/mL | 27.3 ± 1.9 | 28.6 ± 1.7 | 1.2 ± 1.0 |
| BP, 1 mg/mL | 27.3 ± 1.8 | 28.7 ± 1.8 | 1.4 ± 1.5 |
| BP, 5 mg/mL | 27.4 ± 1.9 | 28.3 ± 1.9 | 0.9 ± 1.5 |
| BP, 10 mg/mL | 27.3 ± 1.8 | 28.7 ± 1.8 | 1.3 ± 1.7 |
| BP, 20 mg/mL | 27.3 ± 1.8 | 28.1 ± 1.0 | 0.8 ± 1.6 |

* Significant at P≥0.05 from Acetone Group (Dunnett's Test)

** Significant at P≥0.01 from Acetone Group (Dunnett's Test)

# TABLE 3

## INDIVIDUAL DERMAL IRRITANCY SCORES

### Test Agent: Toluene

Date: 04/30/93 Time Postdose: 24h 1st Dose

| Observation | Animal Number 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/04/93 Time Postdose: 24h 2nd Dose

| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/07/93 Time Postdose: 24h post 3rd Dose

| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 4/16 b |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/13/93 Time Postdose: 72h post 4th Dose

| | Animal Number 13 | 14 | 15 | 16 | Total |
|---|---|---|---|---|---|
| Erythema | 0 | 0 | 1 | 0 | 1/4 |
| Edema | 0 | 0 | 0 | 0 | 0/4 |
| Desquamation | 3 | 2 | 2 | 2 | 4/4 ? |
| Eschar | 0 | 0 | 0 | 0 | 0/4 |
| Alopecia | 0 | 0 | 0 | 0 | 0/4 |
| Discoloration | 0 | 0 | 0 | 0 | 0/4 |
| Fissuring | 0 | 0 | 0 | 0 | 0/4 |
| Ulceration | 0 | 0 | 0 | 0 | 0/4 |

Scoring
0 = no signs
1 = minimal
2 = moderate
3 = marked

# TABLE 3

## INDIVIDUAL DERMAL IRRITANCY SCORES

**Test Agent: Acetone**

Date: 04/30/93 Time Postdose: 24h 1st Dose

| Observation | Animal Number 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/04/93 Time Postdose: 24h 2nd Dose

| | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/07/93 Time Postdose: 24h post 3rd Dose

| | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/13/93 Time Postdose: 72h post 4th Dose

| | Animal Number 29 | 30 | 31 | 32 | Total |
|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0/4 |
| Edema | 0 | 0 | 0 | 0 | 0/4 |
| Desquamation | 0 | 0 | 0 | 0 | 0/4 |
| Eschar | 0 | 0 | 0 | 0 | 0/4 |
| Alopecia | 0 | 0 | 0 | 0 | 0/4 |
| Discoloration | 0 | 0 | 0 | 0 | 0/4 |
| Fissuring | 0 | 0 | 0 | 0 | 0/4 |
| Ulceration | 0 | 0 | 0 | 0 | 0/4 |

**Scoring**
0 = no signs
1 = minimal
2 = moderate
3 = marked

## TABLE 3

## INDIVIDUAL DERMAL IRRITANCY SCORES

**Test Agent: MSO:Toluene**

Date: 04/30/93 Time Postdose: 24h 1st Dose

| Observation | Animal Number 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/04/93 Time Postdose: 24h 2nd Dose

| | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 3/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/07/93 Time Postdose: 24h post 3rd Dose

| | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 3/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 13/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/13/93 Time Postdose: 72h post 4th Dose

| | Animal Number 45 | 46 | 47 | 48 | Total |
|---|---|---|---|---|---|
| Erythema | 0 | 1 | 2 | 2 | 3/4 5 |
| Edema | 0 | 0 | 0 | 0 | 0/4 |
| Desquamation | 1 | 2 | 2 | 3 | 4/4 8 |
| Eschar | 0 | 1 | 0 | 0 | 0/4 1 |
| Alopecia | 0 | 0 | 0 | 0 | 0/4 |
| Discoloration | 0 | 0 | 0 | 0 | 0/4 |
| Fissuring | 0 | 0 | 0 | 0 | 0/4 |
| Ulceration | 0 | 0 | 0 | 0 | 0/4 |

**Scoring**
0 = no signs
1 = minimal
2 = moderate
3 = marked

# TABLE 3

## INDIVIDUAL DERMAL IRRITANCY SCORES

**Test Agent: OLPH, 11.8 µL**

Date: 04/30/93 Time Postdose: 24h 1st Dose

| Observation | Animal Number | | | | | | | | | | | | | | | | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | |
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/04/93 Time Postdose: 24h 2nd Dose

| | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/07/93 Time Postdose: 24h post 3rd Dose

| | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/13/93 Time Postdose: 72h post 4th Dose

| | Animal Number | | | | Total |
|---|---|---|---|---|---|
| | 61 | 62 | 63 | 64 | |
| Erythema | 0 | 0 | 0 | 0 | 0/4 |
| Edema | 0 | 0 | 0 | 0 | 0/4 |
| Desquamation | 0 | 0 | 0 | 0 | 0/4 |
| Eschar | 0 | 0 | 0 | 0 | 0/4 |
| Alopecia | 0 | 0 | 0 | 0 | 0/4 |
| Discoloration | 0 | 0 | 0 | 0 | 0/4 |
| Fissuring | 0 | 0 | 0 | 0 | 0/4 |
| Ulceration | 0 | 0 | 0 | 0 | 0/4 |

**Scoring**
0 = no signs
1 = minimal
2 = moderate
3 = marked

## TABLE 3

## INDIVIDUAL DERMAL IRRITANCY SCORES

**Test Agent: OLPH, 23.5 µL**

Date: 04/30/93 Time Postdose: 24h 1st Dose

| Observation | Animal Number 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/04/93 Time Postdose: 24h 2nd Dose

| | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/07/93 Time Postdose: 24h post 3rd Dose

| | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/13/93 Time Postdose: 72h post 4th Dose

| | Animal Number 77 | 78 | 79 | 80 | Total |
|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0/4 |
| Edema | 0 | 0 | 0 | 0 | 0/4 |
| Desquamation | 0 | 0 | 0 | 0 | 0/4 |
| Eschar | 0 | 0 | 0 | 0 | 0/4 |
| Alopecia | 0 | 0 | 0 | 0 | 0/4 |
| Discoloration | 0 | 0 | 0 | 0 | 0/4 |
| Fissuring | 0 | 0 | 0 | 0 | 0/4 |
| Ulceration | 0 | 0 | 0 | 0 | 0/4 |

Scoring
0 = no signs
1 = minimal
2 = moderate
3 = marked

# TABLE 3

## INDIVIDUAL DERMAL IRRITANCY SCORES

**Test Agent: OLPH, 50 µL**

**Date: 04/30/93** **Time Postdose: 24h 1st Dose**

| Observation | Animal Number | | | | | | | | | | | | | | | | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | |
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

**Date: 05/04/93** **Time Postdose: 24h 2nd Dose**

| | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

**Date: 05/07/93** **Time Postdose: 24h post 3rd Dose**

| | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

**Date: 05/13/93** **Time Postdose: 72h post 4th Dose**

| | Animal Number | | | | Total |
|---|---|---|---|---|---|
| | 93 | 94 | 95 | 96 | |
| Erythema | 0 | 0 | 2 | 0 | 1/4 2 |
| Edema | 0 | 0 | 0 | 0 | 0/4 |
| Desquamation | 0 | 0 | 1 | 0 | 1/4 |
| Eschar | 0 | 0 | 0 | 0 | 0/4 |
| Alopecia | 0 | 0 | 0 | 0 | 0/4 |
| Discoloration | 0 | 0 | 0 | 0 | 0/4 |
| Fissuring | 0 | 0 | 0 | 0 | 0/4 |
| Ulceration | 0 | 0 | 0 | 0 | 0/4 |

**Scoring**
0 = no signs
1 = minimal
2 = moderate
3 = marked

# TABLE 3

## INDIVIDUAL DERMAL IRRITANCY SCORES

**Test Agent: OLPH, 100 µL**

**Date: 04/30/93** Time Postdose: 24h 1st Dose

| Observation | Animal Number 97 | 98 | 99 | 100 | 101 | 102 | 103 | 104 | 105 | 106 | 107 | 108 | 109 | 110 | 111 | 112 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | D | 0 | 0/15 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | D | 0 | 0/15 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | D | 0 | 0/15 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | D | 0 | 0/15 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | D | 0 | 0/15 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | D | 0 | 0/15 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | D | 0 | 0/15 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | D | 0 | 0/15 |

**Date: 05/04/93** Time Postdose: 24h 2nd Dose

| | 97 | 98 | 99 | 100 | 101 | 102 | 103 | 104 | 105 | 106 | 107 | 108 | 109 | 110 | 111 | 112 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | D | 0 | 0/15 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | D | 0 | 0/15 |
| Desquamation | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | D | 0 | 4/15 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | D | 0 | 0/15 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | D | 0 | 0/15 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | D | 0 | 0/15 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | D | 0 | 0/15 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | D | 0 | 0/15 |

**Date: 05/07/93** Time Postdose: 24h post 3rd Dose

| | 97 | 98 | 99 | 100 | 101 | 102 | 103 | 104 | 105 | 106 | 107 | 108 | 109 | 110 | 111 | 112 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | D | 0 | 2/15 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | D | 0 | 0/15 |
| Desquamation | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | D | 0 | 7/15 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | D | 0 | 0/15 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | D | 0 | 0/15 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | D | 0 | 0/15 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | D | 0 | 0/15 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | D | 0 | 0/15 |

**Date: 05/13/93** Time Postdose: 72h post 4th Dose

| | Animal Number 109 | 110 | 111 | 112 | Total |
|---|---|---|---|---|---|
| Erythema | 0 | 0 | D | 1 | 1/3 |
| Edema | 0 | 0 | D | 0 | 0/3 |
| Desquamation | 1 | 1 | D | 0 | 2/3 |
| Eschar | 0 | 0 | D | 0 | 0/3 |
| Alopecia | 0 | 0 | D | 0 | 0/3 |
| Discoloration | 0 | 0 | D | 0 | 0/3 |
| Fissuring | 0 | 0 | D | 0 | 0/3 |
| Ulceration | 0 | 0 | D | 0 | 0/3 |

**Scoring**
0 = no signs
1 = minimal
2 = moderate
3 = marked
D = dead

# TABLE 3

## INDIVIDUAL DERMAL IRRITANCY SCORES

**Test Agent: MSO, 11.8 µL**

Date: 04/30/93 Time Postdose: 24h 1st Dose

| Observation | Animal Number 113 | 114 | 115 | 116 | 117 | 118 | 119 | 120 | 121 | 122 | 123 | 124 | 125 | 126 | 127 | 128 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/04/93 Time Postdose: 24h 2nd Dose

| | 113 | 114 | 115 | 116 | 117 | 118 | 119 | 120 | 121 | 122 | 123 | 124 | 125 | 126 | 127 | 128 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 4/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/07/93 Time Postdose: 24h post 3rd Dose

| | 113 | 114 | 115 | 116 | 117 | 118 | 119 | 120 | 121 | 122 | 123 | 124 | 125 | 126 | 127 | 128 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/13/93 Time Postdose: 72h post 4th Dose

| | Animal Number 125 | 126 | 127 | 128 | Total |
|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0/4 |
| Edema | 0 | 0 | 0 | 0 | 0/4 |
| Desquamation | 0 | 0 | 0 | 0 | 0/4 |
| Eschar | 0 | 0 | 0 | 0 | 0/4 |
| Alopecia | 0 | 0 | 0 | 0 | 0/4 |
| Discoloration | 0 | 0 | 0 | 0 | 0/4 |
| Fissuring | 0 | 0 | 0 | 0 | 0/4 |
| Ulceration | 0 | 0 | 0 | 0 | 0/4 |

**Scoring**
0 = no signs
1 = minimal
2 = moderate
3 = marked

## TABLE 3

## INDIVIDUAL DERMAL IRRITANCY SCORES

**Test Agent: MSO, 23.5 µL**

Date: 04/30/93 Time Postdose: 24h 1st Dose

| Observation | Animal Number 129 | 130 | 131 | 132 | 133 | 134 | 135 | 136 | 137 | 138 | 139 | 140 | 141 | 142 | 143 | 144 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Escher | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/04/93 Time Postdose: 24h 2nd Dose

| | 129 | 130 | 131 | 132 | 133 | 134 | 135 | 136 | 137 | 138 | 139 | 140 | 141 | 142 | 143 | 144 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 6/16 |
| Escher | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/07/93 Time Postdose: 24h post 3rd Dose

| | 129 | 130 | 131 | 132 | 133 | 134 | 135 | 136 | 137 | 138 | 139 | 140 | 141 | 142 | 143 | 144 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1/16 |
| Escher | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/13/93 Time Postdose: 72h post 4th Dose

| | Animal Number 141 | 142 | 143 | 144 | Total |
|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0/4 |
| Edema | 0 | 0 | 0 | 0 | 0/4 |
| Desquamation | 0 | 0 | 0 | 0 | 0/4 |
| Escher | 0 | 0 | 0 | 0 | 0/4 |
| Alopecia | 0 | 0 | 0 | 0 | 0/4 |
| Discoloration | 0 | 0 | 0 | 0 | 0/4 |
| Fissuring | 0 | 0 | 0 | 0 | 0/4 |
| Ulceration | 0 | 0 | 0 | 0 | 0/4 |

Scoring
0 = no signs
1 = minimal
2 = moderate
3 = marked

# TABLE 3

## INDIVIDUAL DERMAL IRRITANCY SCORES

**Test Agent: MSO, 50 µL**

Date: 04/30/93 Time Postdose: 24h 1st Dose

| Observation | Animal Number 145 | 146 | 147 | 148 | 149 | 150 | 151 | 152 | 153 | 154 | 155 | 156 | 157 | 158 | 159 | 160 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/04/93 Time Postdose: 24h 2nd Dose

| | 145 | 146 | 147 | 148 | 149 | 150 | 151 | 152 | 153 | 154 | 155 | 156 | 157 | 158 | 159 | 160 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 8/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/07/93 Time Postdose: 24h post 3rd Dose

| | 145 | 146 | 147 | 148 | 149 | 150 | 151 | 152 | 153 | 154 | 155 | 156 | 157 | 158 | 159 | 160 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/13/93 Time Postdose: 72h post 4th Dose

| | Animal Total 157 | 158 | 159 | 160 | Total |
|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0/4 |
| Edema | 0 | 0 | 0 | 0 | 0/4 |
| Desquamation | 1 | 0 | 2 | 2 | 3/4 5 |
| Eschar | 0 | 0 | 0 | 0 | 0/4 |
| Alopecia | 0 | 0 | 0 | 0 | 0/4 |
| Discoloration | 0 | 0 | 0 | 0 | 0/4 |
| Fissuring | 0 | 0 | 0 | 0 | 0/4 |
| Ulceration | 0 | 0 | 0 | 0 | 0/4 |

Scoring
0 = no signs
1 = minimal
2 = moderate
3 = marked

## TABLE 3

## INDIVIDUAL DERMAL IRRITANCY SCORES

**Test Agent: MSO, 100 µl.**

Date: 04/30/93 Time Postdose: 24h 1st Dose

| Observation | Animal Number 161 | 162 | 163 | 164 | 165 | 166 | 167 | 168 | 169 | 170 | 171 | 172 | 173 | 174 | 175 | 176 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/04/93 Time Postdose: 24h 2nd Dose

| | 161 | 162 | 163 | 164 | 165 | 166 | 167 | 168 | 169 | 170 | 171 | 172 | 173 | 174 | 175 | 176 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 5/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/07/93 Time Postdose: 24h post 3rd Dose

| | 161 | 162 | 163 | 164 | 165 | 166 | 167 | 168 | 169 | 170 | 171 | 172 | 173 | 174 | 175 | 176 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 7/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 8/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/13/93 Time Postdose: 72h post 4th Dose

| | Animal Number 173 | 174 | 175 | 176 | Total | |
|---|---|---|---|---|---|---|
| Erythema | 3 | 0 | 1 | 0 | 2/4 | 4 |
| Edema | 0 | 0 | 0 | 0 | 0/4 | |
| Desquamation | 1 | 2 | 2 | 1 | 4/4 | 6 |
| Eschar | 1 | 0 | 0 | 0 | 1/4 | |
| Alopecia | 0 | 0 | 0 | 0 | 0/4 | |
| Discoloration | 0 | 0 | 0 | 0 | 0/4 | |
| Fissuring | 0 | 0 | 0 | 0 | 0/4 | |
| Ulceration | 0 | 0 | 0 | 0 | 0/4 | |

Scoring
0 = no signs
1 = minimal
2 = moderate
3 = marked

## TABLE 3

## INDIVIDUAL DERMAL IRRITANCY SCORES

**Test Agent: LVD, 11.8 µL**

Date: 04/30/93 Time Postdose: 24h 1st Dose

| Observation | Animal Number 177 | 178 | 179 | 180 | 181 | 182 | 183 | 184 | 185 | 186 | 187 | 188 | 189 | 190 | 191 | 192 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/04/93 Time Postdose: 24h 2nd Dose

| | 177 | 178 | 179 | 180 | 181 | 182 | 183 | 184 | 185 | 186 | 187 | 188 | 189 | 190 | 191 | 192 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/07/93 Time Postdose: 24h post 3rd Dose

| | 177 | 178 | 179 | 180 | 181 | 182 | 183 | 184 | 185 | 186 | 187 | 188 | 189 | 190 | 191 | 192 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/13/93 Time Postdose: 72h post 4th Dose

| | Animal Number 189 | 190 | 191 | 192 | Total |
|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0/4 |
| Edema | 0 | 0 | 0 | 0 | 0/4 |
| Desquamation | 0 | 0 | 0 | 0 | 0/4 |
| Eschar | 0 | 0 | 0 | 0 | 0/4 |
| Alopecia | 0 | 0 | 0 | 0 | 0/4 |
| Discoloration | 0 | 0 | 0 | 0 | 0/4 |
| Fissuring | 0 | 0 | 0 | 0 | 0/4 |
| Ulceration | 0 | 0 | 0 | 0 | 0/4 |

**Scoring**
0 = no signs
1 = minimal
2 = moderate
3 = marked

# TABLE 3

## INDIVIDUAL DERMAL IRRITANCY SCORES

**Test Agent: LVD, 23.5 µL**

Date: 04/30/93 Time Postdose: 24h 1st Dose

| Observation | Animal Number 193 | 194 | 195 | 196 | 197 | 198 | 199 | 200 | 201 | 202 | 203 | 204 | 205 | 206 | 207 | 208 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/04/93 Time Postdose: 24h 2nd Dose

| | 193 | 194 | 195 | 196 | 197 | 198 | 199 | 200 | 201 | 202 | 203 | 204 | 205 | 206 | 207 | 208 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 3/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/07/93 Time Postdose: 24h post 3rd Dose

| | 193 | 194 | 195 | 196 | 197 | 198 | 199 | 200 | 201 | 202 | 203 | 204 | 205 | 206 | 207 | 208 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/13/93 Time Postdose: 72h post 4th Dose

| | Animal Number 205 | 206 | 207 | 208 | Total |
|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0/4 |
| Edema | 0 | 0 | 0 | 0 | 0/4 |
| Desquamation | 0 | 0 | 0 | 0 | 0/4 |
| Eschar | 0 | 0 | 0 | 0 | 0/4 |
| Alopecia | 0 | 0 | 0 | 0 | 0/4 |
| Discoloration | 0 | 0 | 0 | 0 | 0/4 |
| Fissuring | 0 | 0 | 0 | 0 | 0/4 |
| Ulceration | 0 | 0 | 0 | 0 | 0/4 |

Scoring
0 = no signs
1 = minimal
2 = moderate
3 = marked

# TABLE 3

## INDIVIDUAL DERMAL IRRITANCY SCORES

**Test Agent: LVD, 33.3 µL**

Date: 04/30/93 Time Postdose: 24h 1st Dose

| Observation | Animal Number | | | | | | | | | | | | | | | | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | 209 | *210 | 211 | 212 | 213 | 214 | 215 | 216 | 217 | 218 | 219 | 220 | 221 | 222 | 223 | 224 | |
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | D | 0 | 0/15 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | D | 0 | 0/15 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | D | 0 | 0/15 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | D | 0 | 0/15 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | D | 0 | 0/15 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | D | 0 | 0/15 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | D | 0 | 0/15 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | D | 0 | 0/15 |

Date: 05/04/93 Time Postdose: 24h 2nd Dose

| | 209 | *210 | 211 | 212 | 213 | 214 | 215 | 216 | 217 | 218 | 219 | 220 | 221 | 222 | 223 | 224 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | D | 0 | 0/15 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | D | 0 | 0/15 |
| Desquamation | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | D | 0 | 5/15 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | D | 0 | 0/15 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | D | 0 | 0/15 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | D | 0 | 0/15 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | D | 0 | 0/15 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | D | 0 | 0/15 |

Date: 05/07/93 Time Postdose: 24h post 3rd Dose

| | 209 | *210 | 211 | 212 | 213 | 214 | 215 | 216 | 217 | 218 | 219 | 220 | 221 | 222 | 223 | 224 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | D | 0 | 0/15 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | D | 0 | 0/15 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | D | 0 | 0/15 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | D | 0 | 0/15 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | D | 0 | 0/15 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | D | 0 | 0/15 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | D | 0 | 0/15 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | D | 0 | 0/15 |

Date: 05/13/93 Time Postdose: 72h post 4th Dose

| | Animal Number | | | | Total |
|---|---|---|---|---|---|
| | 221 | 222 | 223 | 224 | |
| Erythema | 0 | 0 | D | 0 | 0/3 |
| Edema | 0 | 0 | D | 0 | 0/3 |
| Desquamation | 2 | 0 | D | 0 | 1/3 2 |
| Eschar | 0 | 0 | D | 0 | 0/3 |
| Alopecia | 0 | 0 | D | 0 | 0/3 |
| Discoloration | 0 | 0 | D | 0 | 0/3 |
| Fissuring | 0 | 0 | D | 0 | 0/3 |
| Ulceration | 0 | 0 | D | 0 | 0/3 |

Scoring
0 = no signs
1 = minimal
2 = moderate
3 = marked
D = dead

* Animal #210 lost its ear tag, replaced with ear tag #503

# TABLE 3

## INDIVIDUAL DERMAL IRRITANCY SCORES

**Test Agent: LVD, 100 µL**

Date: 04/30/93 Time Postdose: 24h 1st Dose

| Observation | Animal Number | | | | | | | | | | | | | | | | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | 225 | 226 | 227 | 228 | 229 | 230 | 231 | 232 | 233 | 234 | 235 | 236 | 237 | 238 | 239 | 240 | |
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/04/93 Time Postdose: 24h 2nd Dose

| | 225 | 226 | 227 | 228 | 229 | 230 | 231 | 232 | 233 | 234 | 235 | 236 | 237 | 238 | 239 | 240 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | [illegible] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 4/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/07/93 Time Postdose: 24h post 3rd Dose

| | 225 | 226 | 227 | 228 | 229 | 230 | 231 | 232 | 233 | 234 | 235 | 236 | 237 | 238 | 239 | 240 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 4/16 5 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 6/16 |
| Eschar | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/13/93 Time Postdose: 72h post 4th Dose

| | Animal Number | | | | Total |
|---|---|---|---|---|---|
| | 237 | 238 | 239 | 240 | |
| Erythema | 3 | 0 | 0 | 0 | 1/4 3 |
| Edema | 0 | 0 | 0 | 0 | 0/4 |
| Desquamation | 1 | 1 | 0 | 2 | 3/4 4 |
| Eschar | 0 | 0 | 0 | 0 | 0/4 |
| Alopecia | 0 | 0 | 0 | 0 | 0/4 |
| Discoloration | 0 | 0 | 0 | 0 | 0/4 |
| Fissuring | 2 | 0 | 0 | 0 | 1/4 2 |
| Ulceration | 0 | 0 | 0 | 0 | 0/4 |

**Scoring**
0 = no signs
1 = minimal
2 = moderate
3 = marked

# TABLE 3

## INDIVIDUAL DERMAL IRRITANCY SCORES

**Test Agent: TPA, 0.2125 nmol**

Date: 04/30/93 Time Postdose: 24h 1st Dose

| Observation | Animal Number 241 | 242 | 243 | 244 | 245 | 246 | 247 | 248 | 249 | 250 | 251 | 252 | 253 | 254 | 255 | 256 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/04/93 Time Postdose: 24h 2nd Dose

| | 241 | 242 | 243 | 244 | 245 | 246 | 247 | 248 | 249 | 250 | 251 | 252 | 253 | 254 | 255 | 256 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/07/93 Time Postdose: 24h post 3rd Dose

| | 241 | 242 | 243 | 244 | 245 | 246 | 247 | 248 | 249 | 250 | 251 | 252 | 253 | 254 | 255 | *256 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/13/93 Time Postdose: 72h post 4th Dose

| | Animal Number 253 | 254 | 255 | *256 | Total |
|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0/4 |
| Edema | 0 | 0 | 0 | 0 | 0/4 |
| Desquamation | 0 | 0 | 0 | 0 | 0/4 |
| Eschar | 0 | 0 | 0 | 0 | 0/4 |
| Alopecia | 0 | 0 | 0 | 0 | 0/4 |
| Discoloration | 0 | 0 | 0 | 0 | 0/4 |
| Fissuring | 0 | 0 | 0 | 0 | 0/4 |
| Ulceration | 0 | 0 | 0 | 0 | 0/4 |

Scoring
0 = no signs
1 = minimal
2 = moderate
3 = marked

* Animal #256 lost its ear tag, replaced with ear tag #456

# TABLE 3

## INDIVIDUAL DERMAL IRRITANCY SCORES

**Test Agent: TPA, 0.85 nmol**

**Date: 04/30/93** Time Postdose: 24h 1st Dose

| Observation | Animal Number | | | | | | | | | | | | | | | | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | 257 | 258 | 259 | 260 | 261 | 262 | 263 | 264 | 265 | 266 | 267 | 268 | 269 | 270 | 271 | 272 | |
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

**Date: 05/04/93** Time Postdose: 24h 2nd Dose

| | 257 | 258 | 259 | 260 | 261 | 262 | 263 | 264 | 265 | 266 | 267 | 268 | 269 | 270 | 271 | 272 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 4/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

**Date: 05/07/93** Time Postdose: 24h post 3rd Dose

| | 257 | 258 | 259 | 260 | 261 | 262 | 263 | 264 | 265 | 266 | 267 | 268 | 269 | 270 | 271 | 272 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

**Date: 05/13/93** Time Postdose: 72h post 4th Dose

| | Animal Number | | | | Total |
|---|---|---|---|---|---|
| | 269 | 270 | 271 | 272 | |
| Erythema | 0 | 0 | 0 | 0 | 0/4 |
| Edema | 0 | 0 | 0 | 0 | 0/4 |
| Desquamation | 0 | 0 | 0 | 0 | 0/4 |
| Eschar | 0 | 0 | 0 | 0 | 0/4 |
| Alopecia | 0 | 0 | 0 | 0 | 0/4 |
| Discoloration | 0 | 0 | 0 | 0 | 0/4 |
| Fissuring | 0 | 0 | 0 | 0 | 0/4 |
| Ulceration | 0 | 0 | 0 | 0 | 0/4 |

**Scoring**
0 = no signs
1 = minimal
2 = moderate
3 = marked

# TABLE 3

## INDIVIDUAL DERMAL IRRITANCY SCORES

**Test Agent: TPA, 3.4 nmol**

Date: 04/30/93 Time Postdose: 24h 1st Dose

| Observation | Animal Number 273 | 274 | 275 | 276 | 277 | 278 | 279 | 280 | 281 | 282 | 283 | 284 | 285 | 286 | 287 | 288 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/04/93 Time Postdose: 24h 2nd Dose

| | 273 | 274 | 275 | 276 | 277 | 278 | 279 | 280 | 281 | 282 | 283 | 284 | 285 | 286 | 287 | 288 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 3/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/07/93 Time Postdose: 24h post 3rd Dose

| | 273 | 274 | 275 | 276 | 277 | 278 | 279 | 280 | 281 | 282 | 283 | 284 | 285 | 286 | 287 | 288 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 1 | 6/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/13/93 Time Postdose: 72h post 4th Dose

| | Animal Number 285 | 286 | 287 | 288 | Total |
|---|---|---|---|---|---|
| Erythema | 0 | 0 | 2 | 0 | 1/4 |
| Edema | 0 | 0 | 0 | 0 | 0/4 |
| Desquamation | 0 | 1 | 3 | 1 | 3/4 |
| Eschar | 0 | 0 | 3 | 0 | 1/4 |
| Alopecia | 0 | 0 | 0 | 0 | 0/4 |
| Discoloration | 0 | 0 | 0 | 0 | 0/4 |
| Fissuring | 0 | 0 | 0 | 0 | 0/4 |
| Ulceration | 0 | 0 | 0 | 0 | 0/4 |

**Scoring**
0 = no signs
1 = minimal
2 = moderate
3 = marked

# TABLE 3

## INDIVIDUAL DERMAL IRRITANCY SCORES

**Test Agent: TPA, 13.6 nmol**

Date: 04/30/93 Time Postdose: 24h 1st Dose

| Observation | Animal Number | | | | | | | | | | | | | | | | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | 289 | 290 | 291 | 292 | 293 | 294 | 295 | 296 | 297 | 298 | 299 | 300 | 301 | 302 | 303 | 304 | |
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/04/93 Time Postdose: 24h 2nd Dose

| | 289 | 290 | 291 | 292 | 293 | 294 | 295 | 296 | 297 | 298 | 299 | 300 | 301 | 302 | 303 | 304 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 1 | 2 | 2 | 1 | 1 | 0 | 0 | 2 | 1 | 0 | 0 | 1 | 1 | 9/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/07/93 Time Postdose: 24h post 3rd Dose

| | 289 | 290 | 291 | 292 | 293 | 294 | 295 | 296 | 297 | 298 | 299 | 300 | 301 | 302 | 303 | 304 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 5/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 2 | 1 | 10/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/13/93 Time Postdose: 72h post 4th Dose

| | Animal Number | | | | Total |
|---|---|---|---|---|---|
| | 301 | 302 | 303 | 304 | |
| Erythema | 0 | 0 | 1 | 0 | 1/4 |
| Edema | 0 | 0 | 0 | 0 | 0/4 |
| Desquamation | 0 | 2 | 2 | 2 | 3/4 |
| Eschar | 0 | 0 | 0 | 0 | 0/4 |
| Alopecia | 0 | 0 | 0 | 0 | 0/4 |
| Discoloration | 0 | 0 | 0 | 0 | 0/4 |
| Fissuring | 0 | 0 | 0 | 0 | 0/4 |
| Ulceration | 0 | 0 | 0 | 0 | 0/4 |

Scoring
0 = no signs
1 = minimal
2 = moderate
3 = marked

# TABLE 3

## INDIVIDUAL DERMAL IRRITANCY SCORES

**Test Agent: n-Dodecane, 10 mg**

Date: 04/30/93 Time Postdose: 24h 1st Dose

| Observation | Animal Number | | | | | | | | | | | | | | | | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | 305 | 306 | 307 | 308 | 309 | 310 | 311 | 312 | 313 | 314 | 315 | 316 | 317 | 318 | 319 | 320 | |
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/04/93 Time Postdose: 24h 2nd Dose

| | 305 | 306 | 307 | 308 | 309 | 310 | 311 | 312 | 313 | 314 | 315 | 316 | 317 | 318 | 319 | 320 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/07/93 Time Postdose: 24h post 3rd Dose

| | 305 | 306 | 307 | 308 | 309 | 310 | 311 | 312 | 313 | 314 | 315 | 316 | 317 | 318 | 319 | 320 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/13/93 Time Postdose: 72h post 4th Dose

| | Animal Number | | | | Total |
|---|---|---|---|---|---|
| | 317 | 318 | 319 | 320 | |
| Erythema | 0 | 0 | 0 | 0 | 0/4 |
| Edema | 0 | 0 | 0 | 0 | 0/4 |
| Desquamation | 0 | 0 | 0 | 0 | 0/4 |
| Eschar | 0 | 0 | 0 | 0 | 0/4 |
| Alopecia | 0 | 0 | 0 | 0 | 0/4 |
| Discoloration | 0 | 0 | 0 | 0 | 0/4 |
| Fissuring | 0 | 0 | 0 | 0 | 0/4 |
| Ulceration | 0 | 0 | 0 | 0 | 0/4 |

Scoring
0 = no signs
1 = minimal
2 = moderate
3 = marked

# TABLE 3

## INDIVIDUAL DERMAL IRRITANCY SCORES

**Test Agent: n-Dodecane, 25 mg**

**Date: 04/30/93** Time Postdose: 24h 1st Dose

| Observation | Animal Number 321 | 322 | 323 | 324 | 325 | 326 | 327 | 328 | 329 | 330 | 331 | 332 | 333 | 334 | 335 | 336 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Escher | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

**Date: 05/04/93** Time Postdose: 24h 2nd Dose

| | 321 | 322 | 323 | 324 | 325 | 326 | 327 | 328 | 329 | 330 | 331 | 332 | 333 | 334 | 335 | 336 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2/16 |
| Escher | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

**Date: 05/07/93** Time Postdose: 24h post 3rd Dose

| | 321 | 322 | *323 | 324 | 325 | 326 | 327 | 328 | 329 | 330 | 331 | 332 | 333 | 334 | 335 | 336 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2/16 |
| Escher | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

**Date: 05/13/93** Time Postdose: 72h post 4th Dose

| | Animal Number 333 | 334 | 335 | 336 | Total |
|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0/4 |
| Edema | 0 | 0 | 0 | 0 | 0/4 |
| Desquamation | 0 | 1 | 0 | 0 | 1/4 |
| Escher | 0 | 0 | 0 | 0 | 0/4 |
| Alopecia | 0 | 0 | 0 | 0 | 0/4 |
| Discoloration | 0 | 0 | 0 | 0 | 0/4 |
| Fissuring | 0 | 0 | 0 | 0 | 0/4 |
| Ulceration | 0 | 0 | 0 | 0 | 0/4 |

**Scoring**
0 = no signs
1 = minimal
2 = moderate
3 = marked

* Animal #323 lost its ear tag, replaced with ear tag #451

# TABLE 3

## INDIVIDUAL DERMAL IRRITANCY SCORES

**Test Agent: n-Dodecane, 50 mg**

Date: 04/30/93 Time Postdose: 24h 1st Dose

| Observation | Animal Number 337 | 338 | 339 | 340 | 341 | 342 | 343 | 344 | 345 | 346 | 347 | 348 | 349 | 350 | 351 | 352 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/04/93 Time Postdose: 24h 2nd Dose

| | 337 | 338 | 339 | 340 | 341 | 342 | 343 | 344 | 345 | 346 | 347 | 348 | 349 | 350 | 351 | 352 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/07/93 Time Postdose: 24h post 3rd Dose

| | 337 | 338 | 339 | 340 | 341 | 342 | 343 | 344 | 345 | 346 | 347 | 348 | 349 | 350 | 351 | 352 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/13/93 Time Postdose: 72h post 4th Dose

| | Animal Number 349 | 350 | 351 | 352 | Total |
|---|---|---|---|---|---|
| Erythema | 0 | 0 | 2 | 0 | 1/4 2 |
| Edema | 0 | 0 | 0 | 0 | 0/4 |
| Desquamation | 1 | 0 | 2 | 1 | 3/4 4 |
| Eschar | 0 | 0 | 0 | 0 | 0/4 |
| Alopecia | 0 | 0 | 0 | 0 | 0/4 |
| Discoloration | 0 | 0 | 0 | 0 | 0/4 |
| Fissuring | 0 | 0 | 1 | 0 | 1/4 |
| Ulceration | 0 | 0 | 0 | 0 | 0/4 |

Scoring
0 = no signs
1 = minimal
2 = moderate
3 = marked

# TABLE 3

## INDIVIDUAL DERMAL IRRITANCY SCORES

**Test Agent: n-Dodecane, 100 mg**

Date: 04/30/93 Time Postdose: 24h 1st Dose

| Observation | Animal Number 353 | 354 | 355 | 356 | 357 | 358 | 359 | 360 | 361 | 362 | 363 | 364 | 365 | 366 | 367 | 368 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/04/93 Time Postdose: 24h 2nd Dose

| | 353 | 354 | 355 | 356 | 357 | 358 | *359 | 360 | 361 | 362 | 363 | 364 | 365 | 366 | 367 | 368 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 4/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/07/93 Time Postdose: 24h post 3rd Dose

| | 353 | 354 | 355 | 356 | 357 | 358 | *359 | 360 | 361 | 362 | 363 | 364 | 365 | 366 | 367 | 368 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/13/93 Time Postdose: 72h post 4th Dose

| | Animal Number 365 | 366 | 367 | 368 | Total |
|---|---|---|---|---|---|
| Erythema | 0 | 0 | 2 | 0 | 1/4 2 |
| Edema | 0 | 0 | 0 | 0 | 0/4 |
| Desquamation | 2 | 1 | 0 | 0 | 2/4 3 |
| Eschar | 0 | 0 | 0 | 0 | 0/4 |
| Alopecia | 0 | 0 | 0 | 0 | 0/4 |
| Discoloration | 0 | 0 | 0 | 0 | 0/4 |
| Fissuring | 0 | 0 | 0 | 0 | 0/4 |
| Ulceration | 0 | 0 | 0 | 0 | 0/4 |

Scoring
0 = no signs
1 = minimal
2 = moderate
3 = marked

* Animal #359 lost its ear tag, replaced with ear tag #517

# TABLE 3

## INDIVIDUAL DERMAL IRRITANCY SCORES

**Test Agent: Benzoyl Peroxide , 1 mg**

Date: 04/30/93 Time Postdose: 24h 1st Dose

| Observation | Animal Number | | | | | | | | | | | | | | | | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | 369 | 370 | 371 | 372 | 373 | 374 | 375 | 376 | 377 | 378 | 379 | 380 | 381 | 382 | 383 | 384 | |
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/04/93 Time Postdose: 24h 2nd Dose

| | 369 | 370 | 371 | 372 | 373 | 374 | 375 | 376 | 377 | 378 | 379 | 380 | 381 | 382 | 383 | 384 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/07/93 Time Postdose: 24h post 3rd Dose

| | 369 | 370 | 371 | 372 | 373 | 374 | 375 | 376 | 377 | 378 | 379 | 380 | 381 | 382 | 383 | 384 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/13/93 Time Postdose: 72h post 4th Dose

| | Animal Number | | | | Total |
|---|---|---|---|---|---|
| | 381 | 382 | 383 | 384 | |
| Erythema | 0 | 0 | 0 | 0 | 0/4 |
| Edema | 0 | 0 | 0 | 0 | 0/4 |
| Desquamation | 0 | 0 | 0 | 0 | 0/4 |
| Eschar | 0 | 0 | 0 | 0 | 0/4 |
| Alopecia | 0 | 0 | 0 | 0 | 0/4 |
| Discoloration | 0 | 0 | 0 | 0 | 0/4 |
| Fissuring | 0 | 0 | 0 | 0 | 0/4 |
| Ulceration | 0 | 0 | 0 | 0 | 0/4 |

Scoring
0 = no signs
1 = minimal
2 = moderate
3 = marked

# TABLE 3

## INDIVIDUAL DERMAL IRRITANCY SCORES

**Test Agent: Benzoyl Peroxide , 5 mg**

Date: 04/30/93 Time Postdose: 24h 1st Dose

| Observation | Animal Number | | | | | | | | | | | | | | | | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | 385 | 386 | 387 | 388 | 389 | 390 | 391 | 392 | 393 | 394 | 395 | 396 | 397 | 398 | 399 | 400 | |
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Escher | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/04/93 Time Postdose: 24h 2nd Dose

| | 385 | 386 | 387 | 388 | 389 | 390 | 391 | 392 | 393 | 394 | 395 | 396 | 397 | 398 | 399 | 400 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1/16 |
| Escher | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/07/93 Time Postdose: 24h post 3rd Dose

| | 385 | 386 | 387 | 388 | 389 | 390 | 391 | 392 | 393 | 394 | 395 | 396 | 397 | 398 | 399 | 400 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 5/16 |
| Escher | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/13/93 Time Postdose: 72h post 4th Dose

| | Animal Number | | | | Total |
|---|---|---|---|---|---|
| | 397 | 398 | 399 | 400 | |
| Erythema | 0 | 0 | 0 | 0 | 0/4 |
| Edema | 0 | 0 | 0 | 0 | 0/4 |
| Desquamation | 0 | 0 | 1 | 0 | 1/4 |
| Escher | 0 | 0 | 0 | 0 | 0/4 |
| Alopecia | 0 | 0 | 0 | 0 | 0/4 |
| Discoloration | 0 | 0 | 0 | 0 | 0/4 |
| Fissuring | 0 | 0 | 0 | 0 | 0/4 |
| Ulceration | 0 | 0 | 0 | 0 | 0/4 |

Scoring
0 = no signs
1 = minimal
2 = moderate
3 = marked

# TABLE 3

## INDIVIDUAL DERMAL IRRITANCY SCORES

**Test Agent: Benzoyl Peroxide , 10 mg**

Date: 04/30/93 Time Postdose: 24h 1st Dose

| Observation | Animal Number 401 | 402 | 403 | 404 | 405 | 406 | 407 | 408 | 409 | 410 | 411 | 412 | 413 | 414 | 415 | 416 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/04/93 Time Postdose: 24h 2nd Dose

| | 401 | 402 | 403 | 404 | 405 | 406 | 407 | 408 | 409 | 410 | 411 | 412 | 413 | 414 | 415 | 416 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/07/93 Time Postdose: 24h post 3rd Dose

| | 401 | 402 | 403 | 404 | 405 | 406 | 407 | 408 | 409 | 410 | 411 | 412 | 413 | 414 | 415 | 416 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/13/93 Time Postdose: 72h post 4th Dose

| | Animal Number 413 | 414 | 415 | 416 | Total |
|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0/4 |
| Edema | 0 | 0 | 0 | 0 | 0/4 |
| Desquamation | 0 | 0 | 1 | 0 | 1/4 |
| Eschar | 0 | 0 | 0 | 0 | 0/4 |
| Alopecia | 0 | 0 | 0 | 0 | 0/4 |
| Discoloration | 0 | 0 | 0 | 0 | 0/4 |
| Fissuring | 0 | 0 | 0 | 0 | 0/4 |
| Ulceration | 0 | 0 | 0 | 0 | 0/4 |

**Scoring**
0 = no signs
1 = minimal
2 = moderate
3 = marked

# TABLE 3

## INDIVIDUAL DERMAL IRRITANCY SCORES

**Test Agent: Benzoyl Peroxide , 20 mg**

Date: 04/30/93 Time Postdose: 24h 1st Dose

| Observation | Animal Number 417 | 418 | 419 | 420 | 421 | 422 | 423 | 424 | 425 | 426 | 427 | 428 | 429 | 430 | 431 | 432 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/04/93 Time Postdose: 24h 2nd Dose

| | 417 | 418 | 419 | 420 | 421 | 422 | 423 | 424 | 425 | 426 | 427 | 428 | 429 | 430 | 431 | 432 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 2/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/07/93 Time Postdose: 24h post 3rd Dose

| | 417 | 418 | 419 | 420 | 421 | 422 | 423 | 424 | 425 | 426 | 427 | 428 | 429 | 430 | 431 | 432 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Desquamation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Eschar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Discoloration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Fissuring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |
| Ulceration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/16 |

Date: 05/13/93 Time Postdose: 72h post 4th Dose

| | Animal Number 429 | 430 | 431 | 432 | Total |
|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0/4 |
| Edema | 0 | 0 | 0 | 0 | 0/4 |
| Desquamation | 0 | 0 | 0 | 0 | 0/4 |
| Eschar | 0 | 0 | 0 | 0 | 0/4 |
| Alopecia | 0 | 0 | 0 | 0 | 0/4 |
| Discoloration | 0 | 0 | 0 | 0 | 0/4 |
| Fissuring | 0 | 0 | 0 | 0 | 0/4 |
| Ulceration | 0 | 0 | 0 | 0 | 0/4 |

Scoring
0 = no signs
1 = minimal
2 = moderate
3 = marked



0 0 5 4

Table 4
TOTAL DERMAL IRRITANCY SCORES

| Animal # | 24h post 1st Dose | 24h post 2nd Dose | 24h post 3rd Dose | 72h post 4th Dose |
|---|---|---|---|---|
| *Toluene* | | | | |
| 1 | [1]0 | 0 | 0 | |
| 2 | 0 | 0 | 1 | |
| 3 | 0 | 0 | 0 | |
| 4 | 0 | 0 | 0 | |
| 5 | 0 | 0 | 2 | |
| 6 | 0 | 0 | 0 | |
| 7 | 0 | 0 | 0 | |
| 8 | 0 | 1 | 0 | |
| 9 | 0 | 0 | 1 | |
| 10 | 0 | 0 | 0 | |
| 11 | 0 | 0 | 0 | |
| 12 | 0 | 0 | 0 | |
| 13 | 0 | 0 | 0 | 3 |
| 14 | 0 | 1 | 2 | 2 |
| 15 | 0 | 0 | 0 | 3 |
| 16 | 0 | 0 | 0 | 2 |
| *Acetone* | | | | |
| 17 | 0 | 0 | 0 | |
| 18 | 0 | 0 | 0 | |
| 19 | 0 | 0 | 0 | |
| 20 | 0 | 0 | 0 | |
| 21 | 0 | 0 | 0 | |
| 22 | 0 | 0 | 0 | |
| 23 | 0 | 0 | 0 | |
| 24 | 0 | 0 | 0 | |
| 25 | 0 | 0 | 0 | |
| 26 | 0 | 0 | 0 | |
| 27 | 0 | 0 | 0 | |
| 28 | 0 | 0 | 0 | |
| 29 | 0 | 0 | 0 | 0 |
| 30 | 0 | 0 | 0 | 0 |
| 31 | 0 | 0 | 0 | 0 |
| 32 | 0 | 0 | 0 | 0 |
| *MSO:Toluene* | | | | |
| 33 | 0 | 0 | 1 | |
| 34 | 0 | 1 | 1 | |
| 35 | 0 | 0 | 1 | |
| 36 | 0 | 0 | 3 | |
| 37 | 0 | 0 | 0 | |
| 38 | 0 | 0 | 1 | |
| 39 | 0 | 0 | 0 | |
| 40 | 0 | 0 | 1 | |
| 41 | 0 | 0 | 1 | |
| 42 | 0 | 0 | 1 | |
| 43 | 0 | 0 | 1 | |
| 44 | 0 | 0 | 1 | |
| 45 | 0 | 0 | 1 | 1 |
| 46 | 0 | 1 | 0 | 4 |
| 47 | 0 | 0 | 2 | 4 |
| 48 | 0 | 1 | 2 | 5 |

[1]Maximum possible total score per animal per scoring period is 24

**Table 4**
**TOTAL DERMAL IRRITANCY SCORES**

| Animal # | 24h post 1st Dose | 24h post 2nd Dose | 24h post 3rd Dose | 72h post 4th Dose |
|---|---|---|---|---|
| *OLPH, 11.8 µL* | | | | |
| 49 | [1]0 | 0 | 0 | |
| 50 | 0 | 0 | 0 | |
| 51 | 0 | 0 | 0 | |
| 52 | 0 | 0 | 0 | |
| 53 | 0 | 0 | 0 | |
| 54 | 0 | 0 | 0 | |
| 55 | 0 | 0 | 0 | |
| 56 | 0 | 0 | 0 | |
| 57 | 0 | 0 | 0 | |
| 58 | 0 | 0 | 0 | |
| 59 | 0 | 0 | 0 | |
| 60 | 0 | 0 | 0 | |
| 61 | 0 | 0 | 0 | 0 |
| 62 | 0 | 0 | 0 | 0 |
| 63 | 0 | 0 | 0 | 0 |
| 64 | 0 | 0 | 0 | 0 |
| *OLPH, 23.5 µL* | | | | |
| 65 | 0 | 0 | 0 | |
| 66 | 0 | 0 | 0 | |
| 67 | 0 | 0 | 0 | |
| 68 | 0 | 1 | 1 | |
| 69 | 0 | 0 | 0 | |
| 70 | 0 | 0 | 0 | |
| 71 | 0 | 1 | 0 | |
| 72 | 0 | 0 | 0 | |
| 73 | 0 | 0 | 0 | |
| 74 | 0 | 0 | 0 | |
| 75 | 0 | 0 | 0 | |
| 76 | 0 | 0 | 0 | |
| 77 | 0 | 0 | 0 | 0 |
| 78 | 0 | 0 | 0 | 0 |
| 79 | 0 | 0 | 0 | 0 |
| 80 | 0 | 0 | 0 | 0 |
| *OLPH, 50 µL* | | | | |
| 81 | 0 | 0 | 0 | |
| 82 | 0 | 0 | 0 | |
| 83 | 0 | 0 | 0 | |
| 84 | 0 | 0 | 0 | |
| 85 | 0 | 0 | 0 | |
| 86 | 0 | 0 | 0 | |
| 87 | 0 | 0 | 0 | |
| 88 | 0 | 0 | 0 | |
| 89 | 0 | 0 | 0 | |
| 90 | 0 | 0 | 0 | |
| 91 | 0 | 0 | 0 | |
| 92 | 0 | 0 | 0 | |
| 93 | 0 | 0 | 0 | 0 |
| 94 | 0 | 0 | 0 | 0 |
| 95 | 0 | 0 | 1 | 3 |
| 96 | 0 | 0 | 0 | 0 |

[1]Maximum possible total score per animal per scoring period is 24

**Table 4**
**TOTAL DERMAL IRRITANCY SCORES**

| Animal # | 24h post 1st Dose | 24h post 2nd Dose | 24h post 3rd Dose | 72h post 4th Dose |
|---|---|---|---|---|
| *OLPH, 100 µL* | | | | |
| 97 | [1]0 | 0 | 0 | |
| 98 | 0 | 1 | 1 | |
| 99 | 0 | 0 | 0 | |
| 100 | 0 | 0 | 1 | |
| 101 | 0 | 0 | 1 | |
| 102 | 0 | 1 | 1 | |
| 103 | 0 | 0 | 0 | |
| 104 | 0 | 0 | 0 | |
| 105 | 0 | 1 | 2 | |
| 106 | 0 | 1 | 0 | |
| 107 | 0 | 0 | 1 | |
| 108 | 0 | 0 | 2 | |
| 109 | 0 | 0 | 0 | 1 |
| 110 | 0 | 0 | 0 | 1 |
| 111 | | | | |
| 112 | 0 | 0 | 0 | 1 |
| *MSO, 11.8 µL* | | | | |
| 113 | 0 | 1 | 0 | |
| 114 | 0 | 1 | 0 | |
| 115 | 0 | 0 | 0 | |
| 116 | 0 | 0 | 0 | |
| 117 | 0 | 0 | 0 | |
| 118 | 0 | 1 | 0 | |
| 119 | 0 | 0 | 0 | |
| 120 | 0 | 0 | 0 | |
| 121 | 0 | 0 | 0 | |
| 122 | 0 | 0 | 0 | |
| 123 | 0 | 0 | 0 | |
| 124 | 0 | 1 | 0 | |
| 125 | 0 | 0 | 0 | 0 |
| 126 | 0 | 0 | 0 | 0 |
| 127 | 0 | 0 | 0 | 0 |
| 128 | 0 | 0 | 0 | 0 |
| *MSO, 23.5 µL* | | | | |
| 129 | 0 | 1 | 0 | |
| 130 | 0 | 0 | 0 | |
| 131 | 0 | 0 | 0 | |
| 132 | 0 | 0 | 0 | |
| 133 | 0 | 1 | 0 | |
| 134 | 0 | 0 | 0 | |
| 135 | 0 | 1 | 0 | |
| 136 | 0 | 0 | 0 | |
| 137 | 0 | 1 | 0 | |
| 138 | 0 | 0 | 0 | |
| 139 | 0 | 0 | 0 | |
| 140 | 0 | 0 | 0 | |
| 141 | 0 | 0 | 0 | 0 |
| 142 | 0 | 1 | 1 | 0 |
| 143 | 0 | 1 | 0 | 0 |
| 144 | 0 | 0 | 0 | 0 |

[1]Maximum possible total score per animal per scoring period is 24

**Table 4**
**TOTAL DERMAL IRRITANCY SCORES**

| Animal # | 24h post 1st Dose | 24h post 2nd Dose | 24h post 3rd Dose | 72h post 4th Dose |
|---|---|---|---|---|
| *MSO, 50 µL* | | | | |
| 145 | [1]0 | 1 | 0 | |
| 146 | 0 | 0 | 0 | |
| 147 | 0 | 0 | 0 | |
| 148 | 0 | 1 | 0 | |
| 149 | 0 | 1 | 0 | |
| 150 | 0 | 1 | 2 | |
| 151 | 0 | 0 | 0 | |
| 152 | 0 | 0 | 0 | |
| 153 | 0 | 0 | 0 | |
| 154 | 0 | 1 | 0 | |
| 155 | 0 | 0 | 0 | |
| 156 | 0 | 0 | 0 | |
| 157 | 0 | 1 | 0 | 1 |
| 158 | 0 | 0 | 0 | 0 |
| 159 | 0 | 1 | 1 | 2 |
| 160 | 0 | 1 | 0 | 2 |
| *MSO, 100 µL* | | | | |
| 161 | 0 | 0 | 2 | |
| 162 | 0 | 1 | 2 | |
| 163 | 0 | 0 | 0 | |
| 164 | 0 | 1 | 2 | |
| 165 | 0 | 0 | 0 | |
| 166 | 0 | 0 | 1 | |
| 167 | 0 | 1 | 2 | |
| 168 | 0 | 0 | 0 | |
| 169 | 0 | 0 | 1 | |
| 170 | 0 | 1 | 0 | |
| 171 | 0 | 0 | 2 | |
| 172 | 0 | 0 | 0 | |
| 173 | 0 | 1 | 2 | 5 |
| 174 | 0 | 0 | 0 | 2 |
| 175 | 0 | 0 | 1 | 3 |
| 176 | 0 | 0 | 0 | 1 |
| *LVD, 11.8 µL* | | | | |
| 177 | 0 | 0 | 0 | |
| 178 | 0 | 1 | 0 | |
| 179 | 0 | 0 | 0 | |
| 180 | 0 | 0 | 0 | |
| 181 | 0 | 0 | 0 | |
| 182 | 0 | 0 | 0 | |
| 183 | 0 | 0 | 0 | |
| 184 | 0 | 1 | 0 | |
| 185 | 0 | 0 | 0 | |
| 186 | 0 | 0 | 0 | |
| 187 | 0 | 0 | 0 | |
| 188 | 0 | 0 | 0 | |
| 189 | 0 | 0 | 0 | 0 |
| 190 | 0 | 0 | 0 | 0 |
| 191 | 0 | 0 | 0 | 0 |
| 192 | 0 | 1 | 0 | 0 |

[1]Maximum possible total score per animal per scoring period is 24

**Table 4**
**TOTAL DERMAL IRRITANCY SCORES**

| Animal # | 24h post 1st Dose | 24h post 2nd Dose | 24h post 3rd Dose | 72h post 4th Dose |
|---|---|---|---|---|
| *LVD, 23.5 µL* | | | | |
| 193 | [1]0 | 0 | 0 | |
| 194 | 0 | 0 | 0 | |
| 195 | 0 | 1 | 0 | |
| 196 | 0 | 1 | 0 | |
| 197 | 0 | 0 | 0 | |
| 198 | 0 | 0 | 0 | |
| 199 | 0 | 0 | 0 | |
| 200 | 0 | 0 | 0 | |
| 201 | 0 | 0 | 0 | |
| 202 | 0 | 0 | 0 | |
| 203 | 0 | 0 | 0 | |
| 204 | 0 | 0 | 0 | |
| 205 | 0 | 0 | 0 | 0 |
| 206 | 0 | 1 | 0 | 0 |
| 207 | 0 | 0 | 0 | 0 |
| 208 | 0 | 0 | 0 | 0 |
| *LVD, 33.3 µL* | | | | |
| 209 | 0 | 1 | 0 | |
| 210 | 0 | 1 | 0 | |
| 211 | 0 | 0 | 0 | |
| 212 | 0 | 0 | 0 | |
| 213 | 0 | 0 | 0 | |
| 214 | 0 | 1 | 0 | |
| 215 | 0 | 0 | 0 | |
| 216 | 0 | 0 | 0 | |
| 217 | 0 | 0 | 0 | |
| 218 | 0 | 0 | 0 | |
| 219 | 0 | 1 | 0 | |
| 220 | 0 | 0 | 0 | |
| 221 | 0 | 1 | 0 | 2 |
| 222 | 0 | 0 | 0 | 0 |
| 223 | | | | |
| 224 | 0 | 0 | 0 | 0 |
| *LVD, 100 µL* | | | | |
| 225 | 0 | 1 | 3 | |
| 226 | 0 | 1 | 0 | |
| 227 | 0 | 0 | 1 | |
| 228 | 0 | 0 | 1 | |
| 229 | 0 | 0 | 0 | |
| 230 | 0 | 0 | 0 | |
| 231 | 0 | 0 | 0 | |
| 232 | 0 | 1 | 2 | |
| 233 | 0 | 0 | 0 | |
| 234 | 0 | 0 | 0 | |
| 235 | 0 | 0 | 2 | |
| 236 | 0 | 0 | 0 | |
| 237 | 0 | 1 | 3 | 6 |
| 238 | 0 | 0 | 0 | 1 |
| 239 | 0 | 0 | 0 | 0 |
| 240 | 0 | 0 | 0 | 2 |

[1]Maximum possible total score per animal per scoring period is 24

Table 4
TOTAL DERMAL IRRITANCY SCORES

| Animal # | 24h post 1st Dose | 24h post 2nd Dose | 24h post 3rd Dose | 72h post 4th Dose |
|---|---|---|---|---|
| *TPA, 0.2125 nmol* | | | | |
| 241 | [1]0 | 1 | 0 | |
| 242 | 0 | 1 | 0 | |
| 243 | 0 | 0 | 0 | |
| 244 | 0 | 0 | 0 | |
| 245 | 0 | 0 | 0 | |
| 246 | 0 | 0 | 0 | |
| 247 | 0 | 0 | 0 | |
| 248 | 0 | 0 | 0 | |
| 249 | 0 | 0 | 1 | |
| 250 | 0 | 0 | 0 | |
| 251 | 0 | 0 | 0 | |
| 252 | 0 | 0 | 0 | |
| 253 | 0 | 0 | 0 | 0 |
| 254 | 0 | 0 | 0 | 0 |
| 255 | 0 | 0 | 0 | 0 |
| 256 | 0 | 0 | 0 | 0 |
| *TPA, 0.85 nmol* | | | | |
| 257 | 0 | 0 | 0 | |
| 258 | 0 | 0 | 2 | |
| 259 | 0 | 1 | 0 | |
| 260 | 0 | 0 | 0 | |
| 261 | 0 | 0 | 0 | |
| 262 | 0 | 0 | 0 | |
| 263 | 0 | 0 | 0 | |
| 264 | 0 | 0 | 0 | |
| 265 | 0 | 1 | 0 | |
| 266 | 0 | 0 | 0 | |
| 267 | 0 | 1 | 0 | |
| 268 | 0 | 0 | 0 | |
| 269 | 0 | 0 | 0 | 0 |
| 270 | 0 | 1 | 0 | 0 |
| 271 | 0 | 0 | 0 | 0 |
| 272 | 0 | 0 | 0 | 0 |
| *TPA, 3.4 nmol* | | | | |
| 273 | 0 | 0 | 1 | |
| 274 | 0 | 1 | 1 | |
| 275 | 0 | 0 | 1 | |
| 276 | 0 | 0 | 0 | |
| 277 | 0 | 0 | 0 | |
| 278 | 0 | 0 | 0 | |
| 279 | 0 | 0 | 0 | |
| 280 | 0 | 0 | 0 | |
| 281 | 0 | 0 | 0 | |
| 282 | 0 | 1 | 1 | |
| 283 | 0 | 0 | 0 | |
| 284 | 0 | 0 | 0 | |
| 285 | 0 | 0 | 0 | 0 |
| 286 | 0 | 0 | 0 | 1 |
| 287 | 0 | 2 | 2 | 8 |
| 288 | 0 | 1 | 1 | 1 |

[1]Maximum possible total score per animal per scoring period is 24

Table 4
TOTAL DERMAL IRRITANCY SCORES

| Animal # | 24h post 1st Dose | 24h post 2nd Dose | 24h post 3rd Dose | 72h post 4th Dose |
|---|---|---|---|---|
| *TPA, 13.6 nmol* | | | | |
| 289 | [1]0 | 0 | 2 | |
| 290 | 0 | 0 | 2 | |
| 291 | 0 | 0 | 0 | |
| 292 | 0 | 1 | 1 | |
| 293 | 0 | 2 | 2 | |
| 294 | 0 | 2 | 2 | |
| 295 | 0 | 1 | 1 | |
| 296 | 0 | 1 | 0 | |
| 297 | 0 | 0 | 0 | |
| 298 | 0 | 0 | 2 | |
| 299 | 0 | 3 | 0 | |
| 300 | 0 | 1 | 2 | |
| 301 | 0 | 0 | 0 | 0 |
| 302 | 0 | 0 | 0 | 2 |
| 303 | 0 | 1 | 2 | 3 |
| 304 | 0 | 1 | 1 | 2 |
| *n-Dodecane, 10 mg* | | | | |
| 305 | [1]0 | 0 | 0 | |
| 306 | 0 | 0 | 0 | |
| 307 | 0 | 0 | 0 | |
| 308 | 0 | 0 | 0 | |
| 309 | 0 | 0 | 0 | |
| 310 | 0 | 0 | 0 | |
| 311 | 0 | 0 | 1 | |
| 312 | 0 | 0 | 0 | |
| 313 | 0 | 0 | 0 | |
| 314 | 0 | 0 | 0 | |
| 315 | 0 | 0 | 0 | |
| 316 | 0 | 0 | 0 | |
| 317 | 0 | 1 | 0 | 0 |
| 318 | 0 | 0 | 0 | 0 |
| 319 | 0 | 0 | 0 | 0 |
| 320 | 0 | 0 | 0 | 0 |
| *n-Dodecane, 25 mg* | | | | |
| 321 | [1]0 | 0 | 0 | |
| 322 | 0 | 0 | 0 | |
| 323 | 0 | 0 | 0 | |
| 324 | 0 | 0 | 0 | |
| 325 | 0 | 0 | 1 | |
| 326 | 0 | 0 | 0 | |
| 327 | 0 | 1 | 0 | |
| 328 | 0 | 0 | 0 | |
| 329 | 0 | 1 | 1 | |
| 330 | 0 | 0 | 0 | |
| 331 | 0 | 0 | 0 | |
| 332 | 0 | 0 | 0 | |
| 333 | 0 | 0 | 0 | 0 |
| 334 | 0 | 0 | 0 | 1 |
| 335 | 0 | 0 | 0 | 0 |
| 336 | 0 | 0 | 0 | 0 |

[1]Maximum possible total score per animal per scoring period is 24

Table 4
TOTAL DERMAL IRRITANCY SCORES

| Animal # | 24h post 1st Dose | 24h post 2nd Dose | 24h post 3rd Dose | 72h post 4th Dose |
|---|---|---|---|---|
| *n-Dodecane, 50 mg* | | | | |
| 337 | [1]0 | 0 | 0 | |
| 338 | 0 | 0 | 0 | |
| 339 | 0 | 0 | 0 | |
| 340 | 0 | 0 | 0 | |
| 341 | 0 | 1 | 0 | |
| 342 | 0 | 0 | 0 | |
| 343 | 0 | 0 | 0 | |
| 344 | 0 | 0 | 0 | |
| 345 | 0 | 0 | 0 | |
| 346 | 0 | 0 | 0 | |
| 347 | 0 | 0 | 0 | |
| 348 | 0 | 0 | 0 | |
| 349 | 0 | 1 | 0 | 1 |
| 350 | 0 | 0 | 0 | 0 |
| 351 | 0 | 0 | 0 | 5 |
| 352 | 0 | 0 | 1 | 1 |
| *n-Dodecane, 100 mg* | | | | |
| 353 | [1]0 | 0 | 0 | |
| 354 | 0 | 0 | 0 | |
| 355 | 0 | 1 | 1 | |
| 356 | 0 | 0 | 0 | |
| 357 | 0 | 0 | 0 | |
| 358 | 0 | 0 | 0 | |
| 359 | 0 | 0 | 0 | |
| 360 | 0 | 0 | 0 | |
| 361 | 0 | 0 | 0 | |
| 362 | 0 | 0 | 0 | |
| 363 | 0 | 0 | 0 | |
| 364 | 0 | 1 | 0 | |
| 365 | 0 | 0 | 0 | 2 |
| 366 | 0 | 1 | 0 | 1 |
| 367 | 0 | 1 | 1 | 2 |
| 368 | 0 | 0 | 0 | 0 |
| *Benzoyl Peroxide, 1 mg* | | | | |
| 369 | [1]0 | 0 | 0 | |
| 370 | 0 | 0 | 0 | |
| 371 | 0 | 0 | 0 | |
| 372 | 0 | 0 | 0 | |
| 373 | 0 | 0 | 0 | |
| 374 | 0 | 0 | 0 | |
| 375 | 0 | 0 | 0 | |
| 376 | 0 | 0 | 0 | |
| 377 | 0 | 0 | 0 | |
| 378 | 0 | 0 | 0 | |
| 379 | 0 | 0 | 0 | |
| 380 | 0 | 0 | 0 | |
| 381 | 0 | 0 | 0 | 0 |
| 382 | 0 | 0 | 0 | 0 |
| 383 | 0 | 1 | 0 | 0 |
| 384 | 0 | 0 | 0 | 0 |

[1]Maximum possible total score per animal per scoring period is 24

Table 4
TOTAL DERMAL IRRITANCY SCORES

| Animal # | 24h post 1st Dose | 24h post 2nd Dose | 24h post 3rd Dose | 72h post 4th Dose |
|---|---|---|---|---|
| *Benzoyl Peroxide, 5 mg* | | | | |
| 385 | [1]0 | 0 | 0 | |
| 386 | 0 | 0 | 0 | |
| 387 | 0 | 0 | 0 | |
| 388 | 0 | 0 | 0 | |
| 389 | 0 | 0 | 0 | |
| 390 | 0 | 0 | 0 | |
| 391 | 0 | 0 | 0 | |
| 392 | 0 | 0 | 0 | |
| 393 | 0 | 0 | 1 | |
| 394 | 0 | 0 | 1 | |
| 395 | 0 | 0 | 1 | |
| 396 | 0 | 0 | 1 | |
| 397 | 0 | 0 | 0 | 0 |
| 398 | 0 | 0 | 0 | 0 |
| 399 | 0 | 1 | 1 | 1 |
| 400 | 0 | 0 | 0 | 0 |
| *Benzoyl Peroxide, 10 mg* | | | | |
| 401 | [1]0 | 0 | 0 | |
| 402 | 0 | 0 | 0 | |
| 403 | 0 | 0 | 0 | |
| 404 | 0 | 0 | 0 | |
| 405 | 0 | 0 | 0 | |
| 406 | 0 | 0 | 1 | |
| 407 | 0 | 0 | 0 | |
| 408 | 0 | 0 | 0 | |
| 409 | 0 | 0 | 0 | |
| 410 | 0 | 1 | 0 | |
| 411 | 0 | 0 | 0 | |
| 412 | 0 | 0 | 0 | |
| 413 | 0 | 0 | 0 | 0 |
| 414 | 0 | 0 | 0 | 0 |
| 415 | 0 | 0 | 0 | 1 |
| 416 | 0 | 0 | 0 | 0 |
| *Benzoyl Peroxide, 20 mg* | | | | |
| 417 | [1]0 | 0 | 0 | |
| 418 | 0 | 0 | 0 | |
| 419 | 0 | 0 | 0 | |
| 420 | 0 | 0 | 0 | |
| 421 | 0 | 0 | 0 | |
| 422 | 0 | 0 | 0 | |
| 423 | 0 | 0 | 0 | |
| 424 | 0 | 0 | 0 | |
| 425 | 0 | 0 | 0 | |
| 426 | 0 | 0 | 0 | |
| 427 | 0 | 0 | 0 | |
| 428 | 0 | 0 | 0 | |
| 429 | 0 | 1 | 0 | 0 |
| 430 | 0 | 0 | 0 | 0 |
| 431 | 0 | 0 | 0 | 0 |
| 432 | 0 | 1 | 0 | 0 |

[1]Maximum possible total score per animal per scoring period is 24

TABLE 5
GROSS NECROPSY OBSERVATIONS

| Test Agent | Gelatinous 6/24/48/96h | Thickness 6/24/48/96h | Wrinkled 6/24/48/96h | Scaly 6/24/48/96h | Thin 6/24/48/96h | Granular 6/24/48/96h | Scaly 6/24/48/96h | Red 6/24/48/96h | Bumpy/Raised 6/24/48/96h |
|---|---|---|---|---|---|---|---|---|---|
| Toluene | 0/0/0/0 | 4/3/0/3 | 0/0/4/1 | 3/3/3/3 | 0/0/0/0 | 0/0/1/1 | 2/1/0/0 | 0/1/0/0 | 0/0/0/0 |
| Acetone | 0/0/0/0 | 0/0/0/0 | 0/0/0/0 | 0/0/0/0 | 0/1/0/0 | 0/0/0/0 | 0/0/0/0 | 0/0/0/0 | 0/0/0/0 |
| H2O:Toluene | 2/0/0/1 | 4/3/2/3 | 3/1/3/2 | 0/2/2/2 | 0/1/0/0 | 0/1/4/2 | 0/1/0/0 | 0/0/1/1 | 0/2/0/0 |
| OLPH | | | | | | | | | |
| 11.8 µL | 0/0/0/0 | 0/0/0/0 | 0/0/0/0 | 0/0/0/0 | 2/0/0/0 | 0/0/0/0 | 0/0/0/0 | 0/0/0/0 | 0/0/0/0 |
| 23.5 µL | 0/0/0/0 | 0/0/1/0 | 0/0/2/2 | 0/0/0/0 | 0/1/0/1 | 0/0/0/0 | 0/0/0/0 | 0/0/0/0 | 0/0/0/0 |
| 50 µL | 1/0/0/0 | 3/3/0/1 | 0/1/3/2 | 0/0/0/0 | 0/1/0/1 | 0/0/0/2 | 0/0/0/0 | 0/0/0/0 | 0/0/0/0 |
| 100 µL | 1/0/0/0 | 3/2/1/0 | 0/3/4/2 | 0/1/3/0 | 0/1/1/0 | 0/0/2/0 | 0/0/0/1 | 0/0/0/0 | 0/0/0/0 |
| H2O | | | | | | | | | |
| 11.8 µL | 0/0/0/0 | 1/1/0/1 | 0/1/1/3 | 0/0/1/0 | 0/1/0/0 | 0/0/0/0 | 0/0/0/0 | 0/0/0/0 | 0/0/0/0 |
| 23.5 µL | 0/1/0/0 | 4/3/0/1 | 1/3/4/3 | 0/0/0/0 | 0/0/0/0 | 0/2/1/0 | 0/0/0/0 | 0/0/0/0 | 0/0/0/0 |
| 50 µL | 0/0/0/1 | 3/2/1/4 | 3/0/1/3 | 0/0/1/0 | 0/0/0/0 | 0/3/0/0 | 0/2/1/0 | 0/0/0/0 | 0/0/0/0 |
| 100 µL | 1/2/0/2 | 4/2/1/1 | 1/2/1/3 | 0/1/1/4 | 0/0/0/0 | 1/4/2/1 | 0/0/3/1 | 0/0/1/0 | 0/0/2/0 |
| LVD | | | | | | | | | |
| 11.8 µL | 0/0/0/0 | 0/0/0/2 | 1/1/0/1 | 0/0/0/0 | 0/0/0/0 | 0/0/0/0 | 0/0/0/0 | 0/0/0/1 | 0/0/0/0 |
| 23.5 µL | 0/0/0/0 | 1/1/2/1 | 1/0/0/1 | 0/0/0/1 | 1/0/0/1 | 0/0/0/0 | 0/0/0/0 | 0/0/0/0 | 0/0/0/0 |
| 50 µL | 1/1/0/0 | 3/0/1/1 | 1/0/0/1 | 0/0/0/0 | 0/0/0/0 | 0/1/0/0 | 0/0/2/0 | 1/0/0/0 | 1/0/0/0 |
| 100 µL | 0/0/0/0 | 3/4/4/2 | 2/0/0/1 | 0/0/3/2 | 0/0/0/0 | 0/1/3/0 | 0/1/0/0 | 0/1/1/0 | 0/0/1/0 |
| TPA | | | | | | | | | |
| 0.2125 nmol | 0/0/0/0 | 0/0/0/0 | 0/0/2/0 | 0/0/0/0 | 0/0/2/1 | 0/0/0/0 | 0/0/0/0 | 0/1/0/0 | 0/0/0/0 |
| 0.85 nmol | 0/0/0/0 | 0/0/0/2 | 0/2/3/1 | 0/0/0/0 | 0/1/0/1 | 0/0/0/0 | 0/0/0/0 | 0/0/0/0 | 0/0/0/0 |
| 3.4 nmol | 1/0/0/0 | 1/1/0/2 | 1/1/4/3 | 0/0/0/0 | 0/0/0/1 | 0/0/0/0 | 0/1/0/0 | 0/2/0/0 | 0/0/0/0 |
| 13.6 nmol | 1/0/0/0 | 1/4/3/1 | 2/1/3/4 | 0/2/2/0 | 0/0/0/0 | 0/1/2/0 | 0/0/0/0 | 0/0/0/1 | 0/0/1/0 |
| n-Dodecane | | | | | | | | | |
| 10 mg/mL | 0/0/1/1 | 0/1/0/2 | 0/1/3/4 | 0/0/0/0 | 2/1/0/0 | 0/0/0/0 | 0/0/0/0 | 0/0/0/0 | 0/0/0/0 |
| 25 mg/mL | 0/0/2/0 | 2/1/1/3 | 1/2/3/4 | 0/0/0/0 | 1/1/0/0 | 0/0/1/0 | 0/1/0/0 | 0/1/1/1 | 0/0/0/0 |
| 50 mg/mL | 0/2/0/0 | 2/3/2/1 | 0/4/1/4 | 1/0/1/0 | 0/1/0/0 | 0/0/0/0 | 1/0/0/0 | 0/0/0/0 | 0/0/0/0 |
| 100 mg/mL | 0/0/1/0 | 2/2/2/4 | 0/2/1/4 | 0/0/0/0 | 0/2/2/0 | 0/0/2/1 | 1/1/0/0 | 0/0/0/0 | 0/0/0/0 |
| BPX | | | | | | | | | |
| 1 mg/mL | 0/1/0/0 | 1/3/0/3 | 1/4/2/4 | 0/0/0/0 | 1/0/0/0 | 0/0/0/0 | 0/0/0/0 | 0/0/0/0 | 0/0/0/0 |
| 5 mg/mL | 0/0/0/0 | 1/1/0/1 | 0/2/2/3 | 0/0/0/0 | 0/1/0/0 | 0/0/0/0 | 0/0/0/0 | 0/0/0/0 | 0/0/0/0 |
| 10 mg/mL | 0/0/0/0 | 0/0/0/2 | 0/2/0/3 | 0/0/0/0 | 0/1/0/0 | 0/0/0/0 | 0/0/0/0 | 0/0/0/0 | 0/0/0/0 |
| 20 mg/mL | 0/0/0/0 | 1/3/0/0 | 1/2/2/3 | 0/0/0/0 | 1/0/1/1 | 0/1/0/0 | 0/0/0/0 | 0/1/1/0 | 0/0/0/0 |

# APPENDIX I
## Animal Health Report

FROM

AREA:C11

SHIP TO

MANTECH ENVIRONMENTAL
5C TRIANGLE DRIVE
RESEARCH TRIANGLE PARK, NC

.0.0:93E80780 SHIP DATE-04/05/93

1730811 510 CD-1 MICE FEMALE

| AREA RESULTS: SEROLOGY: | CURRENT POS/TST | YTD POS/TST | BACTERIOLOGY: | CURRENT POS/TST | YTD POS/TST |
|---|---|---|---|---|---|
| SEN | 0/005 | 0/0039 | C.kutscheri | 0/008 | 0/0008 |
| MNV | 0/005 | 0/0039 | M.pulmonis | 0/008 | 0/0008 |
| REO3 | 0/000 | 0/0024 | Salmonella spp. | 0/008 | 0/0008 |
| MVM | 0/000 | 0/0024 | B.bronchiseptica | 0/008 | 0/0008 |
| GD7 | 0/000 | 0/0024 | C.freundii (4280) | 0/008 | 0/0008 |
| PVM | 0/000 | 0/0024 | S.moniliformis ** | 0/008 | 0/0008 |
| MPUL | 0/005 | 0/0039 | | | |
| K * | 0/000 | 0/0008 | | | |
| POLY * | 0/000 | 0/0008 | PARASITOLOGY: | | |
| MAD * | 0/000 | 0/0008 | Ectoparasites | 0/008 | 0/0008 |
| ECTR * | 0/000 | 0/0008 | Endoparasites | 0/008 | 0/0008 |
| LCM * | 0/000 | 0/0008 | | | |
| MCMV * | 0/000 | 0/0008 | | | |
| HANT * | 0/000 | 0/0008 | | | |

GROSS PATHOLOGY: No lesions consistent with an active infectious disease.
REMARKS: (*)-Screened quarterly (**)-Screened annually
Colony is positive for enteric protozoa.

AREA TEST DATES: SEROLOGY- 3/25/93 BACTERIOLOGY- 1/11/93 PARASITOLOGY- 1/11/93

---

ORIGIN: Crl:CD-1(ICR)BR - Caesarean-Derived in 1959 from HaM/ICR (Hauschka and Mirand-Roswell Park Memorial Institute-Swiss) mice.

---

** GENETIC MONITORING SECTION **

You have ordered a Charles River Laboratories (CRL) outbred mouse stock. When you order CRL VAF inbred or hybrid rats and mice, strain-specific biochemical reference profiles with current and historical test data will be provided in this space.

---

HUSBANDRY: These animals were shipped to you from a Charles River Laboratories (CRL) Maximum Barrier Area. They have been fed pasteurized diet and housed on sterilized bedding. CRL strives to maintain other environmental conditions including temperature, humidity, ventilation and photoperiod at optimum levels. Information on these parameters is available upon request.

---

*** PLEASE NOTE ***

The Spring Charles River Update features an article on our expanded transgenic services. To get a copy, please call our Customer Service Department, 1-800-LAB-RATS. We look forward to hearing from you.

APPENDIX II
Feed Analysis

Purina Mills, Inc.
1401 S. Hanley Road
St. Louis, Missouri 63166

TO RICHMOND, IN

CC RICHMOND, IN
DAN HOPKINS, IW

LAB NO 282659 ENTERED 02/02/93 REPORTED 02/16/93 RHI 8002

CERTIFIED RODENT DIET CHECKERS
LOT NUMBER FEB 01 93 18
01 93 16

| ASSAY | ANALYSIS | UNITS |
|---|---|---|
| PROTEIN (N X 6.25) | 21.4 | % |
| FAT (ACID HYDRO.) | 5.75 | % |
| FIBER (CRUDE) | 4.12 | % |
| ARSENIC | 0.279 | PPM |
| CADMIUM | 0.129 | PPM |
| CALCIUM | 0.742 | % |
| LEAD | 0.226 | PPM |
| MERCURY | LESS THAN 0.05 PPM | |
| PHOSPHORUS | 0.709 | % |
| SELENIUM | 0.178 | PPM |

ORGANOPHOSPHATE PEST

| | (PPM) | | (PPM) |
|---|---|---|---|
| DIAZINON | LESS THAN 0.02 | PARATHION | LESS THAN 0.02 |
| DISULFOTON | LESS THAN 0.02 | THIMET | LESS THAN 0.02 |
| ETHION | LESS THAN 0.02 | THIODAN | LESS THAN 0.02 |
| MALATHION | 0.07 | TRITHION | LESS THAN 0.02 |
| METHYL PARATHION | LESS THAN 0.02 | | |

PESTICIDE & PCB

| | (PPM) | | (PPM) |
|---|---|---|---|
| ALDRIN | LESS THAN 0.02 | ENDRIN | LESS THAN 0.02 |
| ALPHA-BHC | LESS THAN 0.02 | HCB | LESS THAN 0.02 |
| BETA-BHC | LESS THAN 0.02 | HEPTACHLOR | LESS THAN 0.02 |
| DELTA-BHC | LESS THAN 0.02 | HEPTACHLOR EPOXIDE | LESS THAN 0.02 |
| CHLORDANE | LESS THAN 0.02 | LINDANE | LESS THAN 0.02 |
| DDE | LESS THAN 0.02 | METHOXYCHLOR | LESS THAN 0.02 |
| DDT..(TOTAL) | LESS THAN 0.02 | MIREX | LESS THAN 0.02 |

APPENDIX II
Feed Analysis (con'd)

Purina Mills, Inc.
1401 S. Hanley Road
St. Louis, Missouri 63166

RT LAB NUMBER 222689 PAGE 2

CERTIFIED RODENT DIET CHECKER®
LOT NUMBER FEB 01 93 1B

PESTICIDE & PCB (CONTINUED)
DIELDRIN..... LESS THAN 0.02 PCB..... LESS THAN 0.15

AFLATOXIN
TOTAL:LESS THAN 5 PPB

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
(1) FOR ASSAY METHODOLOGY - MICHAEL J. MURPHY 314-982-3562
(2) FOR NUTRITIONAL INTERPRETATION-DR DAN HOPKINS 314-768-4876
(3) ALL OTHER QUESTIONS-RICHMOND, IN.: MANUFACTURING PLANT 317-962-9561

CERTIFIED

P 030 795 572

MAIL

:itute

WASHINGTON D.C. NOV 18 '93

U.S. POSTAGE 4 90

Best Available Copy